title: SKOV3.ip1 cells, Lipo_nov_n1

value: Control for SRSF1 knockdown siRNA_1


title: SKOV3.ip1 cells, Lipo_n4

status: Public on Jun 23 2021

type: SRA

city: Sherbrooke

first: Michelle

middle: S

last: Scott

state: Quebec

address: 3201, rue Jean-Mignault

country: Canada

institute: University of Sherbrooke

library_source: transcriptomic

data_processing:
The quality of paired-end RNA-seq reads was examined using Fastqc v0.10.1
The reads are trimmed using Trimmomatic v0.38 with the following parameters LEADING:30 TRAILING:30 SLIDINGWINDOW:4:15 MINLEN:50.
Reads retained by the trimming were further trimmed to a fixed length of 50nt
The reads were aligned against human reference genome hg19 (obtained from UCSC genome browser golden path ftp://hgdownload.soe.ucsc.edu/goldenPath/hg19/chromosomes/) using Tophat (v2.0.9, Bowtie 2.1.0.0, Samtools 0.1.19.0) with default parameters.
Gene expression level was calculated using CoCo v0.2.1p2 and Ensembl genome GRCh37 release 87
Genome_build: hg19
Supplementary_files_format_and_content: coco.TPM.xlsx contains the gene expression in TPM for all samples

molecule: total RNA

organism: Homo sapiens

source_name: Human ovarian cancer cell line SKOV3.ip1

growth_protocol: SKOV-3.ip1 cells are cultivated in 50/50 (v/v) mix of DMEM/Ham F12 supplemented with 10% FBS and 0.2mM L-glutamine.

extract_protocol:
RNA was extracted from mock-transfected and siRNA transfected cells 72h post-transfection.
cDNA library produced with TGIRT (thermostable group II reverse transcriptase)  Purified total RNA was ribodepleted by using a RiboZero Gold (Human/Mouse/Rat) kit (Illumina). The resulting ribodepleted RNAs were fragmented with an NEBNext Magnesium RNA Fragmentation Module (New England Biolabs) by incubation at 94°C for 7 minutes and were then treated with T4 polynucleotide kinase (T4PNK; Epicentre) to remove 3’ phosphates or 2’, 3’ cyclic monophosphates.  cDNAs were synthesized via TGIRT template-switching with either 0.5 or 1µM TGIRT-III reverse transcriptase (Ingex, LLC) for 15 min at 60o C, during which a DNA oligonucleotide containing the complement of an Illumina Read 2 sequencing primer-binding site becomes seamlessly linked to the 5’ cDNA end. After reaction cleanup, a 5’ adenylated DNA oligonucleotide containing the complement of an Illumina Read 1 sequencing primer-binding site is then ligated to the 3’ cDNA end with Thermostable 5’ AppDNA / RNA Ligase (New England Biolabs). Properly ligated cDNAs were amplified by PCR (12 cycles) to synthesize the second strand and add Illumina flowcell capture and index sequences. Libraries were size-selected with Ampure XP beads (Beckman-Coulter) and evaluated on an Agilent 2100 Bioanalyzer

treatment_protocol: siRNAs were transfected into cells at 100nM using Invitrogen Lipofectamine 2000. Lipo samples are treated with Lipofectamine without siRNAs.

tag: cell line

tag: passage

tag: sirna

value: Control for RBFOX2 Knockdown

tag: genotype

value: control


title: SKOV3.ip1 cells, hnRNPC_3_n1

value: hnRNP C knockdown siRNA_3

value: hnRNPC depletion


title: POL2_ChIPSeq_C1_auxin

city: Kiel

first: Elmar

last: Wolf

state: Schleswig-Holstein

address: Rudolf-Höber-Str. 1

department: Biochemical Institute

country: Germany

institute: Christian-Albrechts-University Kiel

library_source: genomic

data_processing:
Fastq files were generated Illumina’s BaseSpace platform and overall sequencing quality was analyzed with the FastQC script.
For ChIP-seq, fastq files were mapped to the human genome (hg19) using Bowtie v2.2.7. and normalized to the sample with the spike in control (mm10).
For 4sU-seq, reads were mapped to hg19 with  Bowtie2,  reads mapping to rRNA,exons and blacklist regions were removed, and then normalized based on read depth.
For SLAM-seq, reads were mapped to hg19 with  Bowtie2. BAM files were normalized based on read depth.
Genome_build: hg19
Supplementary_files_format_and_content: bedGraph files as defined by UCSC (https://genome.ucsc.edu/goldenpath/help/bedgraph.html).

molecule: genomic DNA

growth_protocol: U2OS-SPT6-AID-C1, U2OS-SPT6-AID-C2 and U2OS-WT cells were grown in DMEM supplemented with 10% FCS and 1% penicillin/streptomycin

extract_protocol:
ChIP-seq: Cells were treated with 1% formaldehyde for 5 min at 37°C. After cell lysis, nuclei were re-suspended in RIPA buffer (10 mM Tris/HCl pH 7.5, 150 mM NaCl, 1% NP40, 1% deoxycholic acid (DOC), 0.1% SDS, 1 mM EDTA) and DNA was fragmented to a size <300 bp using Covaris. Chromatin was immunoprecipitated with 15 µg of corresponding antibody for 6 hours. Chromatin was eluted with 1% SDS and crosslinking was reverted overnight. For purification, chloroform/phenol extraction was used.
ChIP-seq: Libraries were prepared according to instructions accompanying the NEBNext Ultra™ II DNA Library Prep Kit for Illumina. Purified DNA was end-repaired, A-tailed, ligated to Illumina adaptors, size-selected (200 bp) and eluted. DNA fragments were amplified by 12 to 17 cycles of PCR and library size was tested with the Fragment Analyzer (Advanced Analytical). The amount of library DNA was quantified using a picogreen assay
RNA-Seq: U2OS cell lysates were spiked 4sU-treated mouse T-cell lysates. Total RNA was isolated using QIAzol and purified with miRNeasy columns and biotinylated. This was followed by  4sU-RNA pulldown pulldown using streptavidin-MyOne beads, followed by purification with RNA minElute columns (Qiagen)
RNA-Seq: 4sU-RNA was used for library preparation with NEBNext rRNA Depletion Kit (Human/Mouse/Rat) and NEBNext Ultra II Directional RNA Library Prep kit. The libraries were amplified with 10-14 PCR cycles depending on the input RNA. The concentration and size distribution of the libraries were determined on a Fragment Analyzer using the NGS Fragment High Sensitivity Analysis Kit (1-6,000 bp; Agilent Technologies). The libraries were sequenced on the NextSeq500 Illumina platform for 75 cycles. Base calling was performed using Illumina’s BaseSpace platform.
3' polyA mRNA-Seq: RNA was isolated using RLT buffer and purified with RNeasy columns and biotinylated. After addition of ERCC spike in (mix1) (Thermo Fisher Scientific),  alkylation of RNA was carried out using 10 mM iodoacetamide (Thermo Fisher Scientific), and the reaction quenched with 1M DTT (Thermo Fisher Scientific). Alkylated RNA was purified with RNA minElute columns (Qiagen).
3' polyA mRNA-Seq: Library preparation was carried out with using QuantSeq kit (Lexogen), and fragments were amplified with 13 PCR cycles.

tag: treatment

value: Auxin

tag: label

tag: antibody

value: Santa Cruz Biotechnology anti-POL2 (A-10), #sc-17798;


title: SKOV3.ip1 cells, Lipo_nov_n2


title: SKOV3.ip1 cells, hnRNPC_2_n1

value: hnRNP C knockdown siRNA_2


title: SKOV3.ip1 cells, hnRNPM_1_n1

value: hnRNP M knockdown siRNA_1

value: hnRNPM depletion


title: SKOV3.ip1 cells, hnRNPM_3_n2

value: hnRNP M knockdown siRNA_3


title: SKOV3.ip1 cells, hnRNPC_2_n3


title: SKOV3.ip1 cells, hnRNPC_3_n3


title: pS2POL2_ChIPSeq_C1_auxin

value: Abcam anti-POL2 (phospho S2), #ab5095;


title: donor_3_a2,6-sialic acid_LPS

city: Amsterdam

first: Joyce

last: Lubbers

state: Noord-Holland

address: De Boelelaan 1108

department: Molecular Cell Biology and Immunology

country: Netherlands

institute: Amsterdam UMC

description:
X66.3p2.6_S120_L005_R1_001..
norm_count_sia_only.txt

data_processing:
Trimming reads for quality using Sickle --> trimmed fastQ files.
Read and sequence alignment using STAR 2.5.4a to create SAM files.
SAMtools 1.3.0 was used to generate BAM files from the SAM files.
Feature counts (R package Subread 1.26.1, R 3.4.0) was used to quantify aligned reads. Multimapping and multi-overlag genes were excluded as described in Subread user guide.
R package EdgeR (version 3.18.1) was used to adjust for library size and trimmed mean of M-values (TMM) Normalization. Genes were filtered and kept if expression was greater than 1 count per million (CPM) in at least 3 samples.
R package EdgeR (version 3.18.1) was used to build a generalized linear model (GLM) to identify the significant differentially expressed genes.
Genome_build: Ensembl human genome GRCh38.p10 release 90.
Supplementary_files_format_and_content: norm_count_sia_only.txt: Tab-delimited text format file with normalized counts created with EdgeR. The content includes sample names, genes and normalized counts for every read.

molecule: polyA RNA

source_name: monocyte-derived dendritic cells

growth_protocol: Monocyte-derived dendritic cells were generated by culturing isolated monocytes for 4 days with IL-4 and GM-CSF.

extract_protocol:
Dendritic cells were harvested and washed with ice-cold PBS after 4 h of dendrimer stimulation, and pooled to obtain sufficient amounts of RNA. Total RNA was extracted with a standard TRIzol isolation protocol (Thermo Fisher Scientific, cat#15596018).
To prepare the mRNA library, 2 μg RNA per sample was used. The library was synthesized using the TruSeq® Stranded mRNA Sample preparation kit (Illumina , cat# RS-122-9004), according to manufacturer’s LS protocol.

treatment_protocol: Unstimulated or stimulation for 4 h with control, α2-3sialic acid or a2-6sialic acid glycodendrimers in the absence or presence of LPS.

tag: cell type

value: monocyte-derived dendritic cells

tag: dendrimer

value: a2,6-sialic acid

tag: lps

value: LPS

tag: donor


title: donor_3_a2,6-sialic acid_no_LPS

description:
X65.32.6_S119_L005_R1_001..
norm_count_sia_only.txt


title: donor_2_a2,6-sialic acid_no_LPS

description:
X63.22.6_S117_L005_R1_001..
norm_count_sia_only.txt


title: donor_1_a2,6-sialic acid_no_LPS

description:
X61.12.6_S115_L005_R1_001..
norm_count_sia_only.txt


title: donor_2_a2,3-sialic acid_no_LPS

description:
X57.22.3_S111_L005_R1_001..
norm_count_sia_only.txt

value: a2,3-sialic acid


title: donor_1_a2,6-sialic acid_LPS

description:
X62.1p2.6_S116_L005_R1_001..
norm_count_sia_only.txt


title: donor_3_a2,3-sialic acid_LPS

description:
X60.3p2.3_S114_L005_R1_001..
norm_count_sia_only.txt


title: donor_1_a2,3-sialic acid_LPS

description:
X56.1p2.3_S110_L005_R1_001..
norm_count_sia_only.txt


title: donor_2_a2,3-sialic acid_LPS

description:
X58.2p2.3_S112_L005_R1_001..
norm_count_sia_only.txt


title: donor_3_control_LPS

description:
X30.3pG_S86_L004_R1_001..
norm_count_sia_only.txt


title: donor_3_a2,3-sialic acid_no_LPS

description:
X59.32.3_S113_L005_R1_001..
norm_count_sia_only.txt


title: donor_2_a2,6-sialic acid_LPS

description:
X64.2p2.6_S118_L005_R1_001..
norm_count_sia_only.txt


title: donor_1_a2,3-sialic acid_no_LPS

description:
X55.12.3_S109_L005_R1_001..
norm_count_sia_only.txt


title: SKOV3.ip1 cells, Lipo_jan_n2

value: Control for hnRNP M knockdown siRNA_3 and SRSF1 knockdown siRNA_3


title: donor_2_unstim_LPS

description:
X22.2p_S146_L006_R1_001..
norm_count_sia_only.txt

value: unstimulated


title: donor_2_control_no_LPS

description:
X27.2G_S83_L004_R1_001..
norm_count_sia_only.txt


title: donor_3_unstim_LPS

description:
X24.3p_S102_L004_R1_001..
norm_count_sia_only.txt


title: donor_2_unstim_no_LPS

description:
X21.2_S145_L006_R1_001..
norm_count_sia_only.txt


title: Hepa.ChIPseq_GR.H11.Dex24h.2

city: Philadelphia

first: Chunjie

last: Jiang

state: PA

address: 3400 Civic Center Boulevard

department: Institute for Diabetes, Obesity, and Metabolism

country: USA

institute: University of Pennsylvania

data_processing:
RNA-seq reads were trimmed using fastp v0.19.5 to remove reads with low quality, too short, or too many N. Trimmed reads were then aligned to human reference genome (hg38) using Hisat2 v2.1 with default parameters. Only unique mapped reads extracted by SAMtools v1.9 were considered for downstream analyses. Quantification of gene annotated in GRCh38 v94 from Ensembl database was estimated using StringTie v1.3.4
ChIP-seq raw reads were trimmed using fastp v0.19.5. Trimmed reads were then aligned to human reference genome (hg38) using Bowtie2 v2.3.0 with default parameters. SAMtools v1.9 was used to extract unique mapped reads and remove duplicated reads. Biological replicates from the same individual were pooled together following by peak calling and de novo motif analyses using HOMER v4.9 with default parameters
ChIA-PET paired-end reads were first removed bridge linker and split into 3 category tags: none-linker containing tags, one-end tags and pair-end tags (PETs). Tags longer than 18 bp were used to mapped to human genome (hg38) by Burrows–Wheeler alignment (BWA) (ref). Duplicated PETs are filtered and uniquely non-redundant PETs were classified into inter-chromosomal PETs, intra-chromosomal PETs (two tags distance >=8 kb) and self-ligated PETs (two tags distance <8 kb). Multiple intra-chromosomal PETs whose respective ends were within 1 kb were then clustered together. PET count of each PET cluster represents the interaction strength. Loops with PETs ≥3 were considered for downstream analysis
Genome_build: hg38
Supplementary_files_format_and_content: Normalized abundance measurement was generated using StringTie.Expression profile were extracted using perl script; bigwig files were generated by Homer

source_name: Hepatocyte

growth_protocol: hiPSCs were induced differentiation with Definitive Endoderm Kit for 4 days at 30-40% confluence 24 hrs post seeding, then were transferred into RPMI-B27 supplemented with BMP-4 and FGF basic in 5% oxygen/5% CO2 for 5 days, and treated with RPMI-B27 supplemented with recombinant human HGF in 5% oxygen/5% CO2 for 5 days, and were treated with HCM Hepatocyte Culture Medium without EGF and hydrocortisone and supplemented with recombinant human oncostatin M for 5 days in ambient oxygen/5% CO2.

extract_protocol:
Total RNA was extracted by using Qiagen RNeasey Mini kit.
DNA was isolated using phenol/chloroform extraction and NaCl/EtOH precipitated with 20 μg glycogen carrier.
The H3K4me3 in-situ ChIA-PET was performed according to the previously described protocol (Li et al., 2017)
RNA libraries were prepared for sequencing by Novogene (CA).
ChIP-seq library was prepared for sequencing according to the amplification protocol from Illumina.

treatment_protocol:
adipocytes were treated with 1uM dexamethasone for 24h beginning at day 24 for RNA-seq, 6h beginning at day 20 for ChIP-seq,
hepatocytes were treated with 1uM dexamethasone for 24h beginning at day 20 for RNA-seq, 6h beginning at day 20 for ChIP-seq, ATAC-seq and ChIA-PET

value: hiPSC-derived HLCs

tag: chip antibody

value: GR


title: donor_1_control_LPS

description:
X26.1pG_S82_L004_R1_001..
norm_count_sia_only.txt

value: control


title: donor_2_control_LPS

description:
X28.2pG_S84_L004_R1_001..
norm_count_sia_only.txt


title: donor_1_unstim_LPS

description:
X20.1p_S144_L006_R1_001..
norm_count_sia_only.txt


title: donor_1_unstim_no_LPS

description:
X19.1_S143_L006_R1_001..
norm_count_sia_only.txt


title: Hepa.ChIPseq_GR.H11.Dex24h.1


title: Hepa.ChIPseq_GR.H11.Dex.2

description: MergedPeakFile.Hepatocyte.txt

data_processing:
RNA-seq reads were trimmed using fastp v0.19.5 to remove reads with low quality, too short, or too many N. Trimmed reads were then aligned to human reference genome (hg38) using Hisat2 v2.1 with default parameters. Only unique mapped reads extracted by SAMtools v1.9 were considered for downstream analyses. Quantification of gene annotated in GRCh38 v94 from Ensembl database was estimated using StringTie v1.3.4
ChIP-seq raw reads were trimmed using fastp v0.19.5. Trimmed reads were then aligned to human reference genome (hg38) using Bowtie2 v2.3.0 with default parameters. SAMtools v1.9 was used to extract unique mapped reads and remove duplicated reads. Biological replicates from the same individual were pooled together following by peak calling and de novo motif analyses using HOMER v4.9 with default parameters
ATAC-seq raw reads were trimmed using fastp v0.19.5. Next, trimmed reads were aligned to human reference genome (hg38) using Bowtie2 v2.3.0 with parameter --very-sensitive. Reads mapped to mitochondria were ignored. SAMtools v1.9 was applied to extract unique mapped reads and remove duplicated reads. Peak calling was performed using Genrich (https://github.com/jsh58/Genrich#contact)
ChIA-PET paired-end reads were first removed bridge linker and split into 3 category tags: none-linker containing tags, one-end tags and pair-end tags (PETs). Tags longer than 18 bp were used to mapped to human genome (hg38) by Burrows–Wheeler alignment (BWA) (ref). Duplicated PETs are filtered and uniquely non-redundant PETs were classified into inter-chromosomal PETs, intra-chromosomal PETs (two tags distance >=8 kb) and self-ligated PETs (two tags distance <8 kb). Multiple intra-chromosomal PETs whose respective ends were within 1 kb were then clustered together. PET count of each PET cluster represents the interaction strength. Loops with PETs ≥3 were considered for downstream analysis
Genome_build: hg38
Supplementary_files_format_and_content: Normalized abundance measurement was generated using StringTie.Expression profile were extracted using perl script; hic files were generated by ChIAPIPE

growth_protocol:
hASCs were cultured in DMEM medium. Confluent hASCs were then transferred into adipogenic medium for 14 days. Then, cells were further cultured in maintenance medium another 7 days and 1.5%BSA medium for additional 2 days.
hiPSCs were induced differentiation with Definitive Endoderm Kit for 4 days at 30-40% confluence 24 hrs post seeding, then were transferred into RPMI-B27 supplemented with BMP-4 and FGF basic in 5% oxygen/5% CO2 for 5 days, and treated with RPMI-B27 supplemented with recombinant human HGF in 5% oxygen/5% CO2 for 5 days, and were treated with HCM Hepatocyte Culture Medium without EGF and hydrocortisone and supplemented with recombinant human oncostatin M for 5 days in ambient oxygen/5% CO2.

extract_protocol:
Total RNA was extracted by using Qiagen RNeasey Mini kit.
DNA was isolated using phenol/chloroform extraction and NaCl/EtOH precipitated with 20 μg glycogen carrier.
Transposed DNA was purified using a QIAGEN MinElute Reaction Cleanup kit. Transposed fragments were subjected to library preparation following manufacturer protocol
The H3K4me3 in-situ ChIA-PET was performed according to the previously described protocol (Li et al., 2017)
RNA libraries were prepared for sequencing by Novogene (CA).
ChIP-seq library was prepared for sequencing according to the amplification protocol from Illumina.
ATAC-seq libraries were sequenced using paired-end, dual-index sequencing on a NextSeq 500 instrument
The H3K4me3 in-situ ChIA-PET was performed according to the previously described protocol (Li et al., 2017)


title: Hepa.ChIPseq_GR.H11.DMSO.2

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.H11.DMSO.1

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.Input

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.H11.Dex.1

description: MergedPeakFile.Hepatocyte.txt


title: donor_3_control_no_LPS

description:
X29.3G_S85_L004_R1_001..
norm_count_sia_only.txt


title: Hepa.ChIPseq_GR.H9.Dex.1

description: MergedPeakFile.Hepatocyte.txt


title: donor_1_control_no_LPS

description:
X25.1G_S81_L004_R1_001..
norm_count_sia_only.txt


title: Hepa.ChIPseq_GR.H9.Dex.2

description: MergedPeakFile.Hepatocyte.txt


title: donor_3_unstim_no_LPS

description:
X23.3_S101_L004_R1_001..
norm_count_sia_only.txt


title: Hepa.ChIPseq_GR.H8.Dex.1

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.H7.Dex.2

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.H7.Dex.1

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.H8.Dex.2

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.H5.Dex.1

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.H5.Dex.2

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.H3.Dex.1

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.H6.Dex.1

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.H4.Dex.2

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.H2.Dex.1

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.H2.Dex.2

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.H4.Dex.1

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.H3.Dex.2

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.H1.Dex.1

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.H10.Dex.2

description: MergedPeakFile.Hepatocyte.txt


title: Hepa.ChIPseq_GR.H10.Dex.1

description: MergedPeakFile.Hepatocyte.txt


title: Beads_only_control_Rep2

city: Cologne

first: Yulia

last: Kargapolova

address: Robert-Koch-Straße 21

department: CMMC

institute: Cologne University

description: RNA-protein complex

data_processing:
Library strategy: sCLIP
demultiplexing
trimming
alignment (STAR)
peak calling (clipper)
Genome_build: hg19
Supplementary_files_format_and_content: called peaks : bed format; files for visualization with igv or ucsc browser - bw format

source_name: Human Caucasian foetal lung fibroblast (IMR90-79)

growth_protocol: IMR90-79 cells were grown in Minimum Essential Medium Eagle supplemented with 20% FBS, x1 penecilin-streptomycin and non-essential amino acids solution till reaching 90% confluency. Cells were further treated in accordance to sCLIP protocol (Kargapolova, Yulia et al. 2017).

extract_protocol:
sCLIP  was  performed  on  ~25  million  UV-crosslinked  nuclei  from  proliferating  IMR90  as  previously described (Kargapolova et al, 2017). RNA-RBP interactions were stabilized with UV crosslinking (245 nm, 150 mJ/cm2 x2 with 1min pause, on ice). The cells were lysed in lysis buffer (Tris-HCl (pH 7,6) (50mM); NaCl (250mM); EDTA (1 mM); Empigen BB (0,5%)), supplemented with protease inhibitor cocktail (Roche) and lysate was treated by TURBO DNase and RNaseT1 (1:1000) 10 min at 37 oC. Endogenous HMGB1/HMGB2 RNA-RBP complexes were immunoprecipitated with a specific primary antibody of interest (3 µg per 500 µl of protein lysate) using magnetic beads (Protein G Dynabeads (Life Technology)) for overnight and washed with 5 washes, 5 min each with lysis buffer. The second round of RNase digestion was performed on the beads for 5 min with 1:1000 diluted RNaseI (Ambion). An aliquot (1/3) of the IP beads was labelled with biotinylated ADP (Jena Bioscience) and T4 RNA-ligase (ThermoFisher) overnight. The signal from RNP complex was visualized using HRP-conjugated Streptavidin (Sigma). The rest of the IP was eluted from the beads, run on standard protein gels and transferred to the nitrocellulose membrane. The region corresponding to RNP complexes was cut and the RNA was eluted using proteinase K (ThermoFisher).
Next, the eluted RNA was polyadenylated. For the cDNA synthesis primers containing random and experimental barcodes were used. At this step the samples were pooled. The cDNA containing T7 promoter sequence was in vitro transcribed, dephosphorylated and treated with PNK, following the 3’ end adaptor ligation using T4 RNA-ligase 2 (a truncated variant, NEB, detailed below). Finally, the aRNA was reversely transcribed and PCR amplified with 10 cycles. Libraries were quality controlled by using Qubit (ThermoFisher) and Bioanalyzer (Agilent).
For the first replica nitrocellulose membrane containing HMGB1- and HMGB2-containing RNA-protein complexes was cut into 2 parts, upper (>25kDa above the expected protein) and lower (between 5kDa and 25kDa above the expected protein size). Libraries were prepared using different barcodes for each fraction, sequenced and reads were merged after mapping. For the second replica no fractionation was performed.

tag: passages

value: no antibody control


title: Hepa.ChIPseq_GR.H6.Dex.2

description: MergedPeakFile.Hepatocyte.txt


title: HMGB2_sCLIP_Rep2

description: RNA-protein complex

value: anti-HMGB2 ab 67282 (4ug)


title: NBK6_repB

first: Axel

last: HILLMER

address: Kerpener Str. 62

department: Institute of Pathology

institute: University of Cologne

description:
Normal human epidermal keratinocyte (NHEK) co-cultured immortalised non-balding dermal papilla cell aggregates, 6 h 10 nM DHT treatment
BK6vsNBK6_gene_exp.diff.txt
BK6vsNBK6_isoform_exp.diff.txt

data_processing:
Sequenced reads were aligned to the Hg19 human genome with TopHat2 (--min-anchor 8 --splice-mismatches 2 --min-intron-length 50 --max-intron-length 500000 --min-isoform-fraction 0.15 --max-multihits 20 --segment-length 25 --segment-mismatches 2 --min-coverage-intron 50 --max-coverage-intron 20000 --min-segment-intron 50 --max-segment-intron 500000 --read-mismatches 2 --read-gap-length 2 --read-edit-dist 2 --read-realign-edit-dist 3 --max-insertion-length 3 --max-deletion-length 3 --mate-inner-dist 50 --mate-std-dev 20 --no-coverage-search --library-type fr-unstranded)
Transcripts were assembled with Cufflinks 2.2.1 (--frag-bias-correct hg19.fa --multi-read-correct --max-bundle-frags 100000000 --library-type fr-unstranded)
Cuffdiff2 was used to quartile normalize and identify differentially-expressed transcripts between BAB aggregates and BAN aggregates (--library-norm-method quartile)
Genome_build: Hg19
Supplementary_files_format_and_content: Cuffdiff2 output file with default settings with quartile normalised FPKM expression value of each sample type and expression level significance (q-value)

source_name: BAN

growth_protocol: 3D fibrous hydrogel scaffolds containing DPC (BAB/BAN) and NHEK were formed by MIPC of two oppositely charged polyelectrolyte solutions. DPC (BAB/BAN) and NHEK were resuspended separately in polycationic water-soluble chitin solution and dispensed between polyanionic sodium alginate solution. The oppositely charged solutions were brought together to form an insoluble polyelectrolyte complex at an interface. Cell-containing fibres formed were drawn upwards and spooled. Each scaffold fabricated consists of DPC (BAB/BAN, 6E5 cells) and NHEK (2E5 cells) in 3:1 ratio.

extract_protocol:
Total RNA was extracted from isolated BAB and BAN aggregates with Qiagen RNeasy kit according to manufacturer’s recommendation
RNA samples of high integrity (RIN value ≥ 8) were then used for RNA-seq library construction. cDNA was generated from 30 ng of extracted RNA with SMARTer Ultra Low Input RNA for Illumina Sequencing (Clontech), followed by RNA-seq library construction with NEBNext DNA Library Prep Master Mix Set for Illumina (NEB). Constructed libraries were multiplex in batches of twelve and 76 bp paired-end sequenced with Illumina HiSeq High Output v3

treatment_protocol: Fabricated MIPC scaffolds were maintained in MIPC media (3 parts DMEM media (DMEM with High Glucose, 4.0 mM L-Glutamine (Hyclone, South Logan, Utah) supplemented with 10% (v/v) fetal bovine serum (Life Technologies, Grand Island, NY), 100 U/ml penicillin G, and 100 mg/ml streptomycin (Sigma-Alrich, St Louis, MO)) and 1 part keratinocyte growth medium(Promocell GmbH, Germany)) for 9 days in an atmosphere of 10% CO2 and 90% air, conditioned in phenol red-free MIPC media (3 part phenol red-free DMEM media and 1 part keratinocyte basal medium) for 24 hr, and treated with 10 nM DHT for 6 hr and 24 hr

value: hTERT-immortalised non-balding dermal papilla cell line (BAN)

tag: time point

value: 6 h

tag: agent

value: 10 nM dihydrotestosterone


title: NBK24_repB

description:
Normal human epidermal keratinocyte (NHEK) co-cultured immortalised non-balding dermal papilla cell aggregates, 24 h 10 nM DHT treatment
BK24vsNBK24_gene_exp.diff.txt
BK24vsNBK24_isoform_exp.diff.txt


title: NBK6_repC


title: NBK24_repA


title: NBK24_repC


title: NBK6_repA


title: Hepa.ChIPseq_GR.H1.Dex.2

description: MergedPeakFile.Hepatocyte.txt


title: NBK0_repC

description:
Normal human epidermal keratinocyte (NHEK) co-cultured immortalised non-balding dermal papilla cell aggregates, no treatment
BK0vsNBK0_gene_exp.diff.txt
BK0vsNBK0_isoform_exp.diff.txt

value: 0 h


title: NBK0_repB


title: NBK0_repA


title: BK24_repC

description:
Normal human epidermal keratinocyte (NHEK) co-cultured immortalised balding dermal papilla cell aggregates, 24 h 10 nM DHT treatment
BK24vsNBK24_gene_exp.diff.txt
BK24vsNBK24_isoform_exp.diff.txt

source_name: BAB

value: hTERT-immortalised balding dermal papilla cell line (BAB)


title: BK24_repB


title: BK24_repA


title: BK6_repA

description:
Normal human epidermal keratinocyte (NHEK) co-cultured immortalised balding dermal papilla cell aggregates, 6 h 10 nM DHT treatment
BK6vsNBK6_gene_exp.diff.txt
BK6vsNBK6_isoform_exp.diff.txt


title: BK6_repB


title: BK6_repC


title: HMGB1_sCLIP_Rep2

description: RNA-protein complex

value: anti-HMGB1 ab 18256 (4ug)


title: BK0_repB

description:
Normal human epidermal keratinocyte (NHEK) co-cultured immortalised balding dermal papilla cell aggregates, no treatment
BK0vsNBK0_gene_exp.diff.txt
BK0vsNBK0_isoform_exp.diff.txt


title: CFT073- ΔryfA-replicate 3

city: Laval

first: Charles

middle: Martin

last: Dozois

state: Québec

address: 531 Boul des Prairies

department: centre Amrand-Frappier Santé Biotechnologie

institute: Institut National de la Recherche scientifique

data_processing:
The libraries were normalized and pooled at 3nM and then denatured in 0.05N NaOH and neutralized using HT1 buffer. ExAMP was added to the mix following the manufacturer’s instructions. The pool now at 200pM was loaded on a Illumina cBot and the flowcell was ran on a HiSeq 4000 for 2x100 cycles (paired-end mode). A phiX library was used as a control and mixed with libraries at 1% level. The Illumina control software was HCS HD 3.4.0.38, the real-time analysis program was RTA v. 2.7.7. Program bcl2fastq2 v2.20 was then used to demultiplex samples and generate fastq reads.
Reads were checked for quality using the FASTQC tool, poor quality reads by Trimmomatic were converted to FastQ format, or “groomed”, for downstream analysis using the FastQ Groomer tool. Bowtie2 (V. 2.3.4.3) was used to align RNA-seq reads to the genome of E. coli CFT073 (GenBank accession no. AE014075.1) with default parameters. Finally, the number of reads mapping to each annotated feature was obtained with HTSeq. Differential expression between WT CFT073 and the ryfA mutant was analyzed using  Degust (v4.1.1) (DOI: 10.5281/zenodo.3258932).
Genome_build: E. coli CFT073 (GenBank accession no. AE014075.1)
Supplementary_files_format_and_content: abundance measurements and Degust expression profiling analysis

organism: Escherichia coli

source_name: Bacteria

growth_protocol: Strains were inoculated  in triplicate 1:100 from an overnight pre-culture grown in LB and grown until mid-log phase with shaking (250 rpm).

extract_protocol:
Total RNA was isolated using the Qiagen RNeasy Protect Bacteria Mini kit. Total RNA was quantified using a NanoDrop Spectrophotometer ND-1000 and its integrity was assessed on a 2100 Bioanalyzer.
rRNA were depleted from 250 ng of total RNA using Ribo-Zero rRNA removal kit specific for bacteria RNA (Illumina). Residual RNA was cleaned up using the Agencourt RNA CleanTM XP Kit and eluted in water. cDNA synthesis was achieved with the NEB Next RNA First Strand Synthesis and NEBNext Ultra Directional RNA Second Strand Synthesis Modules. The remaining steps of library preparation were done using and the NEBNext Ultra II DNA Library Prep Kit for Illumina. Libraries were quantified using the Quant-iT™ PicoGreen® dsDNA Assay Kit and the Kapa Illumina GA with Revised Primers-SYBR Fast Universal kit. Average size fragment was determined using a LabChip GX instrument

tag: medium

value: LB O.D 0.6

tag: strain

value: delta_ryfA (QT5399)


title: CFT073- ΔryfA-replicate 2


title: BK0_repC

tag: cell line


title: CFT073- ΔryfA-replicate 1


title: CFT073- WT-replicate 3

value: WT


title: Phf6KO_MPP_3

city: New York

first: Stuart

middle: Aidan

last: Quinn

state: NY

address: 1130 St Nicholas Ave

department: Institute for Cancer Genetics

institute: Columbia University

data_processing:
BCL files were demultiplexed, and FASTQ files were generated on the BaseSpace platform (Illumina).
Reads were trimmed of contaminating adapter sequences using cutadapt and aligned to the GRCM38-build mouse genome using Bowtie2 in very sensitive mode.
Peaks of transposase-accessible chromatin were called using MACS2 v2.1.1 in SPMR mode on each sample independently and were subsequently centered by symmetrically extending peak summits in the 5′ and 3′ direction by 200 nucleotides. Overlapping peaks were merged into single regions, and the set of all nonoverlapping peaks was used for further analysis.
We used the featureCounts method from the Rsubread v1.32.1 package to quantify the accessibility of each peak in all samples. Statistical analysis of differentially accessible regions was performed using total library size normalization and a negative binomial model in R using the DESeq2 1.22.1 package.
Genome_build: GRCm38

organism: Mus musculus

source_name: MPP

extract_protocol:
Nuclei were isolate from 20,000 LT-HSCs sorted from three individual Phf6 knockout (Phf6−/Y Rosa26+/Cre-ERT2) and Phf6 wild-type (Phf6f/Y Rosa26+/+) mice 8 weeks after tamoxifen treatment.
Nuclei were tagmented using Nextera Tn5 Transposase with single indexed, library-specific sequencing adapters. ATAC-seq libraries were quantified based on the average fragment size according to Bioanalyzer results, pooled at equimolar concentrations, and sequenced as a pool to a total read-depth target of approximately 7 × 107, paired-end, 75-nucleotide-long reads per sample on an Illumina NextSeq 500.

value: Phf6-/Y Rosa26+/Cre-ERT2

value: MPP


title: CFT073- WT-replicate 1


title: Phf6KO_HSC_3

source_name: LT-HSC

value: LT-HSC


title: Phf6KO_MPP_1


title: Phf6KO_MPP_2


title: Phf6KO_HSC_2


title: WT_MPP_3

value: Phf6f/Y Rosa26+/+


title: WT_MPP_1


title: Phf6KO_HSC_1


title: WT_MPP_2


title: WT_HSC_1


title: WT_HSC_2


title: WT_HSC_3


title: CFT073- WT-replicate 2


title: BK0_repA


title: 6d PC rep2

city: Seoul

first: Sangdon

last: Ryu

address: 1, Gwanak-ro, Gwanak-gu

country: South Korea

institute: Department of Agricultural Biotechnology and Research Institute of Agriculture and Life Science

data_processing:
Illumina Casava1.7 software used for basecalling.
QuantSeq 3’ mRNA-Seq reads were aligned using Bowtie2 (Langmead and Salzberg, 2012)
Differentially expressed gene were determined based on counts from unique and multiple alignments using coverage in Bedtools (Quinlan AR, 2010)
The RC (Read Count) data were processed based on quantile normalization method using EdgeR within R (R development Core Team, 2016) using Bioconductor (Gentleman et al.,2004).
Genome_build: mm9
Supplementary_files_format_and_content: Matrix table with raw gene counts for every gene and every sample

source_name: Intestinal

extract_protocol:
Total RNA was isolated using Trizol reagent (Invitrogen). RNA quality was assessed by Agilent 2100 bioanalyzer using the RNA 6000 Nano Chip (Agilent Technologies, Amstelveen, The Netherlands), and RNA quantification was performed using ND-2000 Spectrophotometer (Thermo Inc., DE, USA).
The construction of library was performed using QuantSeq 3’ mRNA-Seq Library Prep Kit (Lexogen, Inc., Austria) according to the manufacturer’s instructions. I

treatment_protocol: Mice were randomly allocated into four groups: NC (saline control), PC (Dextran sodium sulfate-treated positive control), ExDSS (DSS induction with exosome pretreatment), and Ex (exosome treatment without DSS treatment). For exosome pretreatment, 1 mg of bovine colostrum exosomes  were administered orally by gavage to the Ex and ExDSS groups daily for three weeks prior to DSS treatment, while the control groups of NC and PC were treated with phosphate buffered salie (PBS). To induce colitis, mice in two groups of DSS and ExDSS were administered water containing 3% (w/v)  DSS (36-50 kD; MP Biomedicals, LLC, IIkirch, France) for a period of 6 days *ad libitum*.

tag: condition

tag: tissue

value: intestinal

value: wild type


title: 6d PC rep1

value: Dextran sodium sulfate-treated positive control

tag: genotype


title: 6d ExDSS rep1

value: DSS induction with exosome pretreatment


title: 6d Ex rep1

value: exosome treatment without DSS treatment


title: 6d Ex rep2


title: mESCs_RPF_4sU120_rep2

city: Mannheim

first: Johanna

middle: Daniela

last: Schott

address: Franz-Volhard-Straße 6

department: Mannheim Institute for Innate Immunoscience

institute: Heidelberg University

data_processing:
Adapters were removed with the FASTX-toolkit (http://hannonlab.cshl.edu/fastx_toolkit/), retaining only sequences that are at least 28 nt long. The four random nucleotides at the beginning and the end of the reads were trimmed with an in-house developed perl script.
Alignment was performed with bowtie v0.12.8 (Langmead et al., Genome Biology 2009) allowing a maximum of three mismatches and reporting all alignments in the best stratum (settings: -a –best –stratum –v 3). Reads that did not map to tRNA or rRNA sequences (as downloaded from the UCSC Genome Browser) were aligned to the 30mer spike-in (5’-ATCTACGCGCGATAAGGCTAAGCTAGGCAC-3’) and a mouse transcriptome (Gencode VM18 as downloaded from the UCSC Genome Browser wgEncodeGencodeBasicVM18 table).
Reads were filtered with in-house developed perl scripts to retain only reads that are between 25 and 35 nt long, contain no mismatches or only T-to-C transitions with the highest quality score (E) and map to ORFs of isoforms arising from one specific gene (as defined by a common gene symbol). An offset of 12 nt upstream of the start codon and 15 nt upstream of the stop codon with respect to the 5’ end of the read was assumed
Reads containing potential SNPs were removed. Putative SNPs were identified from an untreated sample as positions where at least five reads and 20% of all reads display a T-to-C mismatch.
The number of reads with 0, 1, 2 or 3 T-to-C transitions was counted separately for fragments with 0 to 20 Ts in the reference sequence and separately for each gene, in order to facilitate analyses based on groups of genes
Genome_build: mm10
Supplementary_files_format_and_content: csv files containing the number of reads with 0, 1, 2 or 3 T-to-C transitions, counted separately for fragments with 0 to 20 Ts in the reference sequence, one line per gene

source_name: mESCs

growth_protocol: E14-NKX2-5-EmGFP ESCs (Hsiao et al., PLos One 2008) were maintained on mitomycin treated mouse embryonic fibroblasts (MEFs) in DMEM medium (GIBCO; 11960-044) containing 4.5 mg/ml D-glucose, supplemented with 15% (v/v) FBS (GIBCO, 10270-106); 2 mM L-Glutamine (GIBCO, 25030-024), 0.22 mM 2-mercaptoethanol (Sigma, M3148), 1 mM sodium pyruvate (GIBCO, 11360039), 1% (v/v) NEAA (GIBCO; 11140-034); 100 U/ml penicillin and 0.1 mg/ml streptomycin (GIBCO; 15140-122) and 1,000 U/ml of leukemia inhibitory factor (ESG1107, Millipore). At 80% confluency, mESCs were splitted 1:4.

extract_protocol:
mESCs were washed once in ice-cold PBS containing 100 µg/ml cycloheximide (Roth, 8682.3) by centrifugation at 300 g for 5 min at 4°C and lysed in 300 µl polysome lysis buffer (20 mM Tris-HCl pH 7.4, 10 mM MgCl2, 200 mM KCl2, 1% NP-40, 100 µg/ml cycloheximide, 2 mM DTT, 1 tablet EDTA-free Roche cOmplete Mini Protease Inhibitor per 10 ml) per sample. Lysates were rotated end-over-end for 10 min at 4°C and cleared by centrifugation at 9,300 g for 10 min at 4°C. About 10% of the lysates were saved as input samples. The lysates were subsequently digested with RNase I (240 U per A260; Ambion AM2294) for 5 min at 4°C. Samples were then subjected to 17.5–50% sucrose density gradient centrifugation (for 1 h 45 min at 40,000 rpm and 4°C in a SW60 rotor) and fractions of 250 – 300 µl were collected with a Teledyne Isco Foxy Jr. fractionator directly into 300 µl urea buffer (10 mM Tris-HCl ph 7.5, 350 mM NaCl, 10 mM EDTA, 1% SDS, 7 M urea). RNA was purified from the cytoplasmic lysate (input) or from the monosomal fractions (ribosome footprint) using phenol:chloroform:isoamylalcohol (25:24:1, AppliChem A0944) by phase separation and precipitation with GlycoBlue (Ambion AM9515) in 50 – 60% isopropanol.
Both input and ribosome protected fragments were depleted of ribosomal RNA (rRNA) with the Ribo-Zero Gold Kit (Illumina MRZG126). Input RNA was randomly fragmented by alkaline hydrolysis at pH 10.0 for 12 min at 95°C. Per sample, 0.5 ng spike-in RNA (5’-ATCTACGCGCGA-4sU-AAGGCTAAGCTAGGCACC-3’) was added. Conversion of 4sU to cytidine was induced by treatment with 10 mM NaIO4 in 600 mM NH4Cl pH 8.5 for 15 min at 40°C in a thermomixer. After the conversion reaction, RNA was recovered with G-25 mini Quick Spin Oligo Columns (Roche). Fragmented RNA and ribosome protected fragments were size-selected (25 – 35 nt) on a 15% polyacrylamide Tris-borate-EDTA-urea gel after staining with SybrGold. RNA was eluted from the gel slices by rotating at 4°C overnight in 300 mM NaCl plus RNase OUT (Invitrogen). The gel matrix was removed by centrifugation in a 0.45 µM NanoSep MF tube (PALL). After precipitation with isopropanol and GlycoBlue, end-repair was performed with 10 U T4 PNK (NEB M0201S), 40 U RNase OUT and 1 mM ATP in T4 PNK reaction buffer for 1 h at 37°C. After end-repair with T4 PNK, libraries were prepared with the NEXTflex Small RNA-Seq Kit v3 according to the manufacturer’s manual, using 5 ng RNA for experiment 1 and 8 ng for experiment 2. In order to determine the number of PCR cycles required to obtain a ~ 20 nM library, 1 µl of cDNA per sample was diluted 1:8 and used for a SybrGreen qPCR (forward primer: 5’-GTTCAGAGTTCTACAGTCCGA-3’, reverse primer: 5’-CCTTGGCACCCGAGAATTCCA-3’, SybrGreen master mix: applied biosystems A25742) on a QuantStudio Real-Time PCR System. For library preparation, three cycles less than the highest determined cycle of threshold were used.

treatment_protocol: mESCs were dissolved by trypsinization and mouse embryonic fibroblasts were removed by pre-plating in uncoated dishes for 35 min. For metabolic labeling, mESCs (3 - 5.5 ×106 cells/ml) were treated in suspension at a concentration of 1 × 106 cells/ml medium with 500 µM 4sU. At different time-points after addition of 4sU, cycloheximide was added at a concentration of 100 µg/ml and the cells were pelleted by centrifugation at 300 g for 5 min at RT.

value: mESCs

tag: material

value: ribosome-protected fragments

tag: treatment

value: 4sU, 120 min


title: mESCs_RPF_4sU60_rep2

value: 4sU, 60 min


title: mESCs_IN_4sU90_rep2

value: Input

value: 4sU, 90 min


title: mESCs_IN_4sU60_rep2


title: mESCs_IN_4sU120_rep2


title: mESCs_RPF_4sU120_rep1


title: mESCs_RPF_4sU90_rep1


title: mESCs_RPF_4sU60_rep1


title: mESCs_IN_4sU60_rep1


title: mESCs_IN_4sU120_rep1


title: mESCs_IN_4sU90_rep1


title: 6d NC rep1

value: saline control


title: 6d NC rep2


title: 6d ExDSS rep2


title: ActD4_mESC

description: cytoplasmic RNA

data_processing:
Reads were mapped with STAR v2.5.3a (Dobin et al., Bioinformatics 2012) to a reference of the mouse genome (mm10), providing the basic set of Gencode VM18 as downloaded from the UCSC Genome Browser wgEncodeGencodeBasicVM18 table as transcript annotations, allowing up to 2 mismatches and chimeric read detection with a minimum of 10 nt per segment  (--chimSegmentMin 10).
Read counts were summarized at the gene level with the featureCounts function of the subread package v1.6.3 (Liao et al., Bioinformatics 2014), requiring that a read is completely contained within an exon to be counted.
Circular RNAs were detected with the CIRCexplorer2 v2.3.5 functions parse and annotate (Zhang et al., Genome Research 2016).
For normalization, read counts were subsequently divided by the sum of all reads spanning circRNA junctions in the corresponding sample.
Linear regression was performed on ln-transformed read counts. Half-lives were calculated from the slope of the regression line with the equation: ln(2) / -slope.
Genome_build: mm10
Supplementary_files_format_and_content: csv file containing raw read counts per gene, expression values after normalization to circRNA junction reads, half-lives in hours and the coefficient of determination (R2) of the linear regression used for determination of half-lives

molecule: cytoplasmic RNA

growth_protocol: E14-NKX2-5-EmGFP ESCs (Hsiao et al., PLos One 2008) were maintained on mouse feeders in Knockout DMEM medium (Thermo Fisher Scientific, 10829018) containing 4.5 mg/ml D-glucose, supplemented with 10% serum replacement (Thermo Fisher Scientific, 10828028), 2 mM L-glutamine, 0.1 mM 2-mercaptoethanol, 1 mM sodium pyruvate, 1% penicillin-streptomycin and 1000 U/ml leukemia inhibitory factor. Before differentiation, ESCs were dissociated and grown on 0.1% gelatin (Sigma, G9391) coated 10-cm dishes in Neurobasal medium:DMEM/F12 (1:1; Thermo Fisher Scientific, 21103049 and 21331020) supplemented with 2000 U/ml LIF and 10  ng/ml BMP4 (R&D, 314-BP) for 2 days.

extract_protocol:
RNA was extracted with the GeneMatrix universal RNA purification kit (Roboklon).
After depletion of rRNA, sequencing libraries were prepared with the NEBNext Ultra II Directional RNA Library Prep Kit by the Cell Networks Deep Sequencing Core Facility of Heidelberg University.

treatment_protocol: Transcription was inhibited by adding 10 µg/ml Actinomycin D (ApplicChem, A1489,0005) for 0, 2, 4 and 6 h.

value: ActD, 4h


title: ActD0_mESC

description: cytoplasmic RNA

value: untreated


title: RPF_4sU30_exp2

growth_protocol: RAW264.7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco) supplemented with 10% (v/v) fetal bovine serum (FBS, Biochrome), 2 mM L-Glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin (all PAN Biotech) at 37°C in a humidified atmosphere with 5% CO2. Every two to three days, cells were carefully detached by scraping in warm 1x PBS and diluted 1:10. On the day before experiments, RAW264.7 macrophages were seeded at a density of 1.2 x 107 cells per 10 cm dish (Sarstedt, 83.3902).

extract_protocol:
Cells were washed once in ice-cold 1 x PBS supplemented with 100 µg/ml cycloheximide (Roth, 8682.3), and harvested by scraping in polysome lysis buffer (20 mM Tris-HCl pH 7.4, 10 mM MgCl2, 200 mM KCl2, 1% NP-40, 100 µg/ml cycloheximide, 2 mM DTT, 1 tablet EDTA-free Roche cOmplete Mini Protease Inhibitor per 10 ml). Lysates were rotated end-over-end for 10 min at 4°C and cleared by centrifugation at 9,300 g for 10 min at 4°C. About 10% of the lysates were saved as input samples. The lysates were subsequently digested with RNase I (240 U per A260; Ambion AM2294) for 5 min at 4°C. Samples were then subjected to 17.5â€“50% sucrose density gradient centrifugation (for 1 h 45 min at 40,000 rpm and 4°C in a SW60 rotor) and fractions of 250 â€“ 300 µl were collected with a Teledyne Isco Foxy Jr. fractionator directly into 300 µl urea buffer (10 mM Tris-HCl ph 7.5, 350 mM NaCl, 10 mM EDTA, 1% SDS, 7 M urea). RNA was purified from the cytoplasmic lysate (input) or from the monosomal fractions (ribosome footprint) using phenol:chloroform:isoamylalcohol (25:24:1, AppliChem A0944) by phase separation and precipitation with GlycoBlue (Ambion AM9515) in 50 â€“ 60% isopropanol.
Both input and ribosome protected fragments were depleted of ribosomal RNA (rRNA) with the Ribo-Zero Gold Kit (Illumina MRZG126). Input RNA was randomly fragmented by alkaline hydrolysis at pH 10.0 for 12 min at 95°C. Per sample, 0.5 ng spike-in RNA (5â€™-ATCTACGCGCGA-4sU-AAGGCTAAGCTAGGCACC-3â€™) was added. Conversion of 4sU to cytidine was induced by treatment with 10 mM NaIO4 in 600 mM NH4Cl pH 8.5 for 15 min at 40°C in a thermomixer. After the conversion reaction, RNA was recovered with G-25 mini Quick Spin Oligo Columns (Roche). Fragmented RNA and ribosome protected fragments were size-selected (25 â€“ 35 nt) on a 15% polyacrylamide Tris-borate-EDTA-urea gel after staining with SybrGold. RNA was eluted from the gel slices by rotating at 4°C overnight in 300 mM NaCl plus RNase OUT (Invitrogen). The gel matrix was removed by centrifugation in a 0.45 µM NanoSep MF tube (PALL). After precipitation with isopropanol and GlycoBlue, end-repair was performed with 10 U T4 PNK (NEB M0201S), 40 U RNase OUT and 1 mM ATP in T4 PNK reaction buffer for 1 h at 37°C. After end-repair with T4 PNK, libraries were prepared with the NEXTflex Small RNA-Seq Kit v3 according to the manufacturerâ€™s manual, using 5 ng RNA for experiment 1 and 8 ng for experiment 2. In order to determine the number of PCR cycles required to obtain a ~ 20 nM library, 1 µl of cDNA per sample was diluted 1:8 and used for a SybrGreen qPCR (forward primer: 5â€™-GTTCAGAGTTCTACAGTCCGA-3â€™, reverse primer: 5â€™-CCTTGGCACCCGAGAATTCCA-3â€™, SybrGreen master mix: applied biosystems A25742) on a QuantStudio Real-Time PCR System. For library preparation, three cycles less than the highest determined cycle of threshold were used (12 cycles for experiment 1 and 11 cycles for experiment 2).

treatment_protocol: RAW264.7 cells were treated with 200  M 4sU (Sigma T4509) for the indicated time-points.

value: 4sU, 30 min


title: ActD6_mESC

description: cytoplasmic RNA

value: ActD, 6h


title: ActD2_mESC

description: cytoplasmic RNA

value: ActD, 2h


title: mESCs_RPF_4sU90_rep2


title: IN_4sU40_exp2

value: 4sU, 40 min


title: IN_4sU20_exp2

value: 4sU, 20 min


title: RPF_4sU40_exp2


title: RPF_4sU20_exp2


title: RPF_4sU120_exp1


title: RPF_4sU90_exp1


title: RPF_4sU60_exp1


title: IN_4sU30_exp2


title: RPF_4sU0_exp1


title: IN_4sU120_exp1


title: IN_4sU90_exp1


title: LPS16_IN

data_processing:
Adapters were removed with the FASTX-toolkit (http://hannonlab.cshl.edu/fastx_toolkit/), retaining only sequences that are at least 28 nt long. The four random nucleotides at the beginning and the end of the reads were trimmed with an in-house developed perl script.
Alignment was performed with bowtie v0.12.8 (Langmead et al., Genome Biology 2009) allowing a maximum of two mismatches and reporting all alignments in the best stratum (settings: -a –best –stratum –v 2). Reads that did not map to tRNA or rRNA sequences (as downloaded from the UCSC Genome Browser) were aligned to a mouse transcriptome (Gencode VM18 as downloaded from the UCSC Genome Browser wgEncodeGencodeBasicVM18 table).
Reads were filtered with in-house developed perl scripts to retain only reads that are between 25 and 35 nt long and map to ORFs of isoforms arising from one specific gene (as defined by a common gene symbol). An offset of 12 nt upstream of the start codon and 15 nt upstream of the stop codon with respect to the 5’end of the read was assumed.
We resampled reads that could be uniquely assigned to ORFs to obtain exactly the same number of reads per sample (~ 6.7 million), in order to avoid different degrees of noise due to sampling error between IN and FP samples as well as between different time-points
Normalization was performed using size factors obtained with the median ratio method of the DeSeq2 package, v1.18.1 (Love et al., Genome Biology 2014).
Genome_build: mm10
Supplementary_files_format_and_content: Raw read counts as well as DESeq2-normalized expression values

extract_protocol:
Cells were washed once in ice-cold 1 x PBS supplemented with 100 µg/ml cycloheximide (Roth, 8682.3), and harvested by scraping in polysome lysis buffer (20 mM Tris-HCl pH 7.4, 10 mM MgCl2, 200 mM KCl2, 1% NP-40, 100 µg/ml cycloheximide, 2 mM DTT, 1 tablet EDTA-free Roche cOmplete Mini Protease Inhibitor per 10 ml). Lysates were rotated end-over-end for 10 min at 4°C and cleared by centrifugation at 9,300 g for 10 min at 4°C. About 10% of the lysates were saved as input samples. The lysates were subsequently digested with RNase I (240 U per A260; Ambion AM2294) for 5 min at 4°C. Samples were then subjected to 17.5–50% sucrose density gradient centrifugation (for 1 h 45 min at 40,000 rpm and 4°C in a SW60 rotor) and fractions of 250 – 300 µl were collected with a Teledyne Isco Foxy Jr. fractionator directly into 300 µl urea buffer (10 mM Tris-HCl ph 7.5, 350 mM NaCl, 10 mM EDTA, 1% SDS, 7 M urea). RNA was purified from the cytoplasmic lysate (input) or from the monosomal fractions (ribosome footprint) using phenol:chloroform:isoamylalcohol (25:24:1, AppliChem A0944) by phase separation and precipitation with GlycoBlue (Ambion AM9515) in 50 – 60% isopropanol.
Both input and ribosome protected fragments were depleted of ribosomal RNA (rRNA) with the Ribo-Zero Gold Kit (Illumina MRZG126). Input RNA was randomly fragmented by alkaline hydrolysis at pH 10.0 for 12 min at 95°C. Fragmented RNA and ribosome protected fragments were size-selected (25 – 35 nt) on a 15% polyacrylamide Tris-borate-EDTA-urea gel after staining with SybrGold. RNA was eluted from the gel slices by rotating at 4°C overnight in 300 mM NaCl plus RNase OUT (Invitrogen). The gel matrix was removed by centrifugation in a 0.45 µM NanoSep MF tube (PALL). After precipitation with isopropanol and GlycoBlue, end-repair was performed with 10 U T4 PNK (NEB M0201S), 40 U RNase OUT and 1 mM ATP in T4 PNK reaction buffer for 1 h at 37°C. After end-repair with T4 PNK, libraries were prepared with the NEXTflex Small RNA-Seq Kit v3 according to the manufacturer’s manual, using 2 ng RNA. In order to determine the number of PCR cycles required to obtain a ~ 20 nM library, 1 µl of cDNA per sample was diluted 1:8 and used for a SybrGreen qPCR (forward primer: 5’-GTTCAGAGTTCTACAGTCCGA-3’, reverse primer: 5’-CCTTGGCACCCGAGAATTCCA-3’, SybrGreen master mix: applied biosystems A25742) on a QuantStudio Real-Time PCR System. For library preparation, three cycles less than the highest determined cycle of threshold were used (14 cycles).

treatment_protocol: RAW264.7 macrophages were stimulated with 100 ng/ml LPS (E. coli O111:B4, Sigma L2630) for the indicated time-points.

value: LPS, 16 h


title: IN_4sU40_exp1


title: IN_4sU0_exp1


title: LPS75_IN

value: LPS 75 min


title: LPS60_IN

value: LPS, 60 min


title: LPS90_IN

value: LPS 90 min


title: LPS15_IN

value: LPS, 15 min


title: LPS30_IN

value: LPS, 30 min


title: LPS45_IN

value: LPS, 45 min


title: RPF_4sU20_exp1

value: ribosome-protected fragments


title: RPF_4sU40_exp1


title: LPS45_RPF


title: LPS30_RPF


title: LPS15_RPF


title: LPS16_RPF


title: LPS75_RPF


title: LPS90_RPF


title: LPS60_RPF


title: A-Messier_3-4

description: Srsf3 deleted Srsf3Fl/Fl-βMHC-Cre

data_processing:
The quality of paired-end RNA-seq reads was examined using Fastqc v0.10.1
The reads are trimmed using Trimmomatic v0.38 with the following parameters LEADING:30 TRAILING:30 SLIDINGWINDOW:4:15 MINLEN:50.
Transcript abundance was first estimated using Kallisto v0.46.0 with 100 bootstraps and Ensembl mouse genome mm.GRCm38, then aggregated into gene abundance estimation using biomaRt v2.40.3 with Ensembl annotations and summarized using tximport v1.12.3
Differential expression analysis was performed with DESeq2 v1.24.0
RNA-seq reads were first aligned using Vast-tools v2.2.2 to mouse genome mm9 with default parameters
Samples of the same condition were then merged to increase read coverage following the developers’ recommendation.
Differential splicing analysis was performed using Vast-tools subcommand diff with default parameters
Sashimi plots for selected events were generated using ggsashimi
Genome_build: mm10 (expression) and mm9 (splicing)
Supplementary_files_format_and_content: kallisto-h5-deseq2.xlsx contains differentially expressed genes
Supplementary_files_format_and_content: VAST-TOOLS.xlsx contains differentially spliced events

source_name: Mouse heart

growth_protocol: Srsf3-floxed mice were breeded with a specific Cre overexpressing transgenic mice: βMHC-Cre (constitutive Cre recombinase expressed under Myh7 promoter regulation in cardiomyocytes during in utero development).

extract_protocol:
Total RNA extractions were performed on tissues using Trizol (Invitrogen) with chloroform, following the manufacturer’s protocol.
The library was built with QIAseq ™ Stranded Total RNA Lib Kit (Qiagen 180753), from 5ul (2ng) of mRNA.

treatment_protocol: No-treatment

value: Heart

value: Srsf3 cKO


title: A-Messier_3-8

description: Srsf3 deleted Srsf3Fl/Fl-βMHC-Cre


title: A-Messier_2-2

description: Srsf3 deleted Srsf3Fl/Fl-βMHC-Cre


title: IN_4sU60_exp1

value: Input

value: 4sU, 60 min


title: ActD2

data_processing:
Reads were mapped with STAR v2.5.3a (Dobin et al., Bioinformatics 2012) to a reference of the mouse genome (mm10), providing the basic set of Gencode VM18 as downloaded from the UCSC Genome Browser wgEncodeGencodeBasicVM18 table as transcript annotations, allowing up to 2 mismatches and chimeric read detection with a minimum of 10 nt per segment  (--chimSegmentMin 10).
Read counts were summarized at the gene level with the featureCounts function of the subread package v1.6.3 (Liao et al., Bioinformatics 2014), requiring that a read is completely contained within an exon to be counted.
Circular RNAs were detected with the CIRCexplorer2 v2.3.5 functions parse and annotate (Zhang et al., Genome Research 2016).
For normalization, read counts were subsequently divided by the sum of all reads spanning circRNA junctions in the corresponding sample.
Linear regression was performed on ln-transformed read counts. Half-lives were calculated from the slope of the regression line with the equation: ln(2) / -slope.
Genome_build: mm10
Supplementary_files_format_and_content: csv file containing raw read counts per gene, expression values after normalization to circRNA junction reads, half-lives in hours and the coefficient of determination (R2) of the linear regression used for determination of half-lives. The 6 h time-point was omitted for the calculation of half-lives, because prolonged exposure to ActD apparently inhibited decay.

growth_protocol: RAW264.7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco) supplemented with 10% (v/v) fetal bovine serum (FBS, Biochrome), 2 mM L-Glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin (all PAN Biotech) at 37°C in a humidified atmosphere with 5% CO2. Every two to three days, cells were carefully detached by scraping in warm 1x PBS and diluted 1:10. On the day before experiments, cells were seeded at a density of 2.18 x 10^5 cells/cm2.


title: ActD0

value: untreated


title: ActD6

value: ActD, 6h


title: ActD4

value: ActD, 4h


title: IN_4sU20_exp1


title: A-Messier_3-6

description: control Srsf3Fl/Fl


title: A-Messier_1-1

description: control Srsf3Fl/Fl


title: A-Messier_3-5

description: control Srsf3Fl/Fl


title: LPS0_IN


title: Hepa.ChIAPET_H3K4me3.H8.2.Dex

description: The bridge linker sequence CGCGATATCTTATCTGACT

value: hiPSC-derived HLCs


title: Hepa.ChIAPET_H3K4me3.H9.2.Dex


title: Hepa.ChIAPET_H3K4me3.H11.2.Dex


title: Hepa.ChIAPET_H3K4me3.H11.2.DMSO


title: LPS0_RPF


title: Hepa.ChIAPET_H3K4me3.H6.2.Dex


title: Hepa.ChIAPET_H3K4me3.H3.2.Dex


title: Adip.ChIPseq_GR.A7.Dex.1

description: MergedPeakFile.Adipocyte.txt

data_processing:
none provided by the submitter
Genome_build: hg38

source_name: Adipocyte

extract_protocol: none provided by the submitter

value: hASC-derived adipocytes

value: GR


title: Adip.ChIPseq_GR.A5.Dex.1

description: MergedPeakFile.Adipocyte.txt


title: Adip.ChIPseq_GR.A6.Dex.2

description: MergedPeakFile.Adipocyte.txt


title: Adip.ChIPseq_GR.A4.Dex.1

description: MergedPeakFile.Adipocyte.txt


title: Adip.ChIPseq_GR.A8.Dex.2

description: MergedPeakFile.Adipocyte.txt


title: Adip.ChIPseq_GR.A3.Dex.2

description: MergedPeakFile.Adipocyte.txt


title: Adip.ChIPseq_GR.A8.Dex.1

description: MergedPeakFile.Adipocyte.txt


title: Adip.ChIPseq_GR.Input

description: MergedPeakFile.Adipocyte.txt


title: Adip.ChIPseq_GR.A5.Dex.2

description: MergedPeakFile.Adipocyte.txt


title: Adip.ChIPseq_GR.A2.Dex.2

description: MergedPeakFile.Adipocyte.txt


title: Adip.ChIPseq_GR.A6.Dex.1

description: MergedPeakFile.Adipocyte.txt


title: Adip.ChIPseq_GR.A7.Dex.2

description: MergedPeakFile.Adipocyte.txt


title: Adip.ChIPseq_GR.A2.Dex.1

description: MergedPeakFile.Adipocyte.txt


title: Adip.ChIPseq_GR.A3.Dex.1

description: MergedPeakFile.Adipocyte.txt


title: Hepa.ChIAPET_H3K4me3.H11.Dex


title: Hepa.ChIAPET_H3K4me3.H11.DMSO


title: Adip.ChIPseq_GR.A1.Dex.1

description: MergedPeakFile.Adipocyte.txt


title: Adip.ChIPseq_GR.A1.Dex.2

description: MergedPeakFile.Adipocyte.txt


title: Hepa.ChIAPET_H3K4me3.H9.Dex


title: Hepa.ChIAPET_H3K4me3.H8.Dex


title: Hepa.ChIAPET_H3K4me3.H6.Dex


title: Hepa.ChIAPET_H3K4me3.H3.Dex


title: Adip.ChIPseq_GR.A4.Dex.2

description: MergedPeakFile.Adipocyte.txt


title: EC0456 Esophageal Cancer

type: RNA

city: Kanagawa

first: Satoko

last: Takizawa

address: kamakurashi

country: Japan

institute: Toray industries inc

hyb_protocol: Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.

scan_protocol: 3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).

data_processing: The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.

source_name: Serum

label_protocol: miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.

extract_protocol: Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).

tag: disease state

value: Esophageal Cancer

tag: Sex

value: Female

tag: age

tag: Stage

value: I


title: EC0079 Esophageal Cancer


title: EC0535 Esophageal Cancer


title: EC0487 Esophageal Cancer


title: EC0134 Esophageal Cancer


title: EC0445 Esophageal Cancer


title: EC0055 Esophageal Cancer


title: EC0100 Esophageal Cancer


title: EC0280 Esophageal Cancer


title: EC0127 Esophageal Cancer


title: EC0404 Esophageal Cancer


title: EC0513 Esophageal Cancer


title: EC0402 Esophageal Cancer


title: EC0225 Esophageal Cancer


title: EC0149 Esophageal Cancer


title: EC0416 Esophageal Cancer


title: EC0312 Esophageal Cancer


title: EC0443 Esophageal Cancer


title: EC0346 Esophageal Cancer


title: EC0361 Esophageal Cancer


title: EC0245 Esophageal Cancer


title: EC0253 Esophageal Cancer


title: EC0140 Esophageal Cancer


title: EC0136 Esophageal Cancer

value: Male


title: EC0372 Esophageal Cancer


title: EC0031 Esophageal Cancer


title: EC0455 Esophageal Cancer


title: EC0403 Esophageal Cancer


title: EC0321 Esophageal Cancer


title: EC0481 Esophageal Cancer


title: EC0450 Esophageal Cancer


title: EC0103 Esophageal Cancer


title: EC0231 Esophageal Cancer


title: EC0063 Esophageal Cancer


title: EC0249 Esophageal Cancer


title: EC0115 Esophageal Cancer


title: EC0154 Esophageal Cancer


title: EC0003 Esophageal Cancer


title: EC0101 Esophageal Cancer


title: EC0187 Esophageal Cancer


title: EC0362 Esophageal Cancer


title: EC0214 Esophageal Cancer


title: CC0151 Colorectal Cancer

value: Colorectal Cancer


title: CC0018 Colorectal Cancer


title: EC0043 Esophageal Cancer


title: CC0184 Colorectal Cancer


title: EC0317 Esophageal Cancer


title: EC0436 Esophageal Cancer


title: EC0025 Esophageal Cancer


title: CC0316 Colorectal Cancer


title: CC1428 Colorectal Cancer


title: CC1450 Colorectal Cancer


title: EC0036 Esophageal Cancer


title: CC1546 Colorectal Cancer


title: CC0214 Colorectal Cancer


title: EC0576 Esophageal Cancer


title: EC0199 Esophageal Cancer


title: CC1308 Colorectal Cancer


title: CC1436 Colorectal Cancer


title: CC1435 Colorectal Cancer


title: CC0028 Colorectal Cancer


title: CC1251 Colorectal Cancer


title: CC1437 Colorectal Cancer


title: CC1133 Colorectal Cancer


title: CC0950 Colorectal Cancer


title: CC0265 Colorectal Cancer


title: CC0012 Colorectal Cancer


title: CC1170 Colorectal Cancer


title: CC1424 Colorectal Cancer


title: CC1204 Colorectal Cancer


title: CC0269 Colorectal Cancer


title: CC0979 Colorectal Cancer


title: CC1421 Colorectal Cancer


title: CC0160 Colorectal Cancer


title: CC1412 Colorectal Cancer


title: CC1520 Colorectal Cancer


title: CC0136 Colorectal Cancer


title: CC1471 Colorectal Cancer


title: CC1514 Colorectal Cancer


title: CC0223 Colorectal Cancer


title: CC0029 Colorectal Cancer


title: CC1505 Colorectal Cancer


title: CC0678 Colorectal Cancer


title: CC1434 Colorectal Cancer


title: CC1145 Colorectal Cancer


title: CC1164 Colorectal Cancer


title: CC0823 Colorectal Cancer


title: CC1320 Colorectal Cancer


title: CC0408 Colorectal Cancer


title: CC1001 Colorectal Cancer


title: CC0282 Colorectal Cancer


title: CC1242 Colorectal Cancer


title: CC1198 Colorectal Cancer


title: CC1452 Colorectal Cancer


title: XB1000 Non-cancer C

value: Non-cancer C


title: CC1175 Colorectal Cancer


title: CC1550 Colorectal Cancer


title: CC1165 Colorectal Cancer


title: CC0308 Colorectal Cancer


title: XB0985 Non-cancer C


title: XB0966 Non-cancer C


title: XB0956 Non-cancer C


title: XB0967 Non-cancer C


title: XB0969 Non-cancer C


title: XB0971 Non-cancer C


title: XB0984 Non-cancer C


title: XB0943 Non-cancer C


title: XB0942 Non-cancer C


title: XB0948 Non-cancer C


title: XB0947 Non-cancer C


title: XB0940 Non-cancer C


title: XB0941 Non-cancer C


title: XB0945 Non-cancer C


title: CC0797 Colorectal Cancer


title: XB0935 Non-cancer C


title: XB0939 Non-cancer C


title: XB0930 Non-cancer C


title: XB0931 Non-cancer C


title: XB0934 Non-cancer C


title: XB0915 Non-cancer C


title: XB0919 Non-cancer C


title: XB0920 Non-cancer C


title: XB0951 Non-cancer C


title: XB0923 Non-cancer C


title: XB0928 Non-cancer C


title: XB0911 Non-cancer C


title: XB0917 Non-cancer C


title: XB0922 Non-cancer C


title: XB0912 Non-cancer C


title: XB0910 Non-cancer C


title: XB0898 Non-cancer C


title: XB0892 Non-cancer C


title: XB0897 Non-cancer C


title: XB0889 Non-cancer C


title: XB0886 Non-cancer C


title: XB0893 Non-cancer C


title: XB0887 Non-cancer C


title: XB0896 Non-cancer C


title: XB0884 Non-cancer C


title: XB0881 Non-cancer C


title: XB0872 Non-cancer C


title: XB0879 Non-cancer C


title: XB0873 Non-cancer C


title: XB0875 Non-cancer C


title: XB0878 Non-cancer C


title: XB0871 Non-cancer C


title: XB0908 Non-cancer C


title: XB0868 Non-cancer C


title: XB0869 Non-cancer C


title: XB0866 Non-cancer C


title: XB0864 Non-cancer C


title: XB0865 Non-cancer C


title: XB0867 Non-cancer C


title: XB0863 Non-cancer C


title: XB0859 Non-cancer C


title: XB0882 Non-cancer C


title: XB0858 Non-cancer C


title: XB0874 Non-cancer C


title: XB0856 Non-cancer C


title: XB0852 Non-cancer C


title: XB0853 Non-cancer C


title: XB0850 Non-cancer C


title: XB0846 Non-cancer C


title: XB0847 Non-cancer C


title: XB0842 Non-cancer C


title: EC0532 Esophageal Cancer


title: XB0845 Non-cancer C


title: XB0841 Non-cancer C


title: XB0839 Non-cancer C


title: XB0834 Non-cancer C


title: XB0861 Non-cancer C


title: XB0833 Non-cancer C


title: XB0825 Non-cancer C


title: XB0857 Non-cancer C


title: XB0830 Non-cancer C


title: XB0819 Non-cancer C


title: XB0827 Non-cancer C


title: XB0829 Non-cancer C


title: XB0854 Non-cancer C


title: XB0821 Non-cancer C


title: XB0822 Non-cancer C


title: XB0815 Non-cancer C


title: XB0816 Non-cancer C


title: XB0813 Non-cancer C


title: XB0811 Non-cancer C


title: XB0835 Non-cancer C


title: XB0828 Non-cancer C


title: XB0804 Non-cancer C


title: XB0794 Non-cancer C


title: XB0799 Non-cancer C


title: XB0808 Non-cancer C


title: XB0806 Non-cancer C


title: XB0780 Non-cancer C


title: XB0823 Non-cancer C


title: XB0791 Non-cancer C


title: XB0798 Non-cancer C


title: XB0775 Non-cancer C


title: XB0755 Non-cancer C


title: XB0778 Non-cancer C


title: XB0762 Non-cancer C


title: XB0818 Non-cancer C


title: XB0769 Non-cancer C


title: XB0753 Non-cancer C


title: XB0745 Non-cancer C


title: XB0741 Non-cancer C


title: XB0733 Non-cancer C


title: XB0743 Non-cancer C


title: XB0731 Non-cancer C


title: XB0715 Non-cancer C


title: XB0719 Non-cancer C


title: XB0709 Non-cancer C


title: XB0713 Non-cancer C


title: XB0711 Non-cancer C


title: XB0696 Non-cancer C


title: XB0706 Non-cancer C


title: XB0707 Non-cancer C


title: XB0754 Non-cancer C


title: XB0694 Non-cancer C


title: XB0680 Non-cancer C


title: XB0700 Non-cancer C


title: XB0699 Non-cancer C


title: XB0677 Non-cancer C


title: XB0695 Non-cancer C


title: XB0703 Non-cancer C


title: XB0752 Non-cancer C


title: XB0704 Non-cancer C


title: XB0693 Non-cancer C


title: XB0651 Non-cancer C


title: XB0631 Non-cancer C


title: XB0664 Non-cancer C


title: XB0675 Non-cancer C


title: XB0619 Non-cancer C


title: XB0609 Non-cancer C


title: XB0613 Non-cancer C


title: XB0612 Non-cancer C


title: XB0599 Non-cancer C


title: XB0595 Non-cancer C


title: XB0593 Non-cancer C


title: XB0628 Non-cancer C


title: XB0591 Non-cancer C


title: XB0572 Non-cancer C


title: XB0577 Non-cancer C


title: XB0581 Non-cancer C


title: XB0584 Non-cancer C


title: XB0547 Non-cancer C


title: XB0556 Non-cancer C


title: XB0560 Non-cancer C


title: XB0568 Non-cancer C


title: XB0561 Non-cancer C


title: XB0566 Non-cancer C


title: XB0551 Non-cancer C


title: XB0607 Non-cancer C


title: XB0570 Non-cancer C


title: XB0565 Non-cancer C


title: XB0548 Non-cancer C


title: XB0596 Non-cancer C


title: XB0528 Non-cancer C


title: XB0540 Non-cancer C


title: XB0535 Non-cancer C


title: XB0536 Non-cancer C


title: XB0516 Non-cancer C


title: XB0517 Non-cancer C


title: XB0503 Non-cancer C


title: XB0502 Non-cancer C


title: XB0567 Non-cancer C


title: XB0472 Non-cancer C


title: XB0464 Non-cancer C


title: XB0419 Non-cancer C


title: XB0411 Non-cancer C


title: XB0388 Non-cancer C


title: XB0403 Non-cancer C


title: XB0413 Non-cancer C


title: XB0386 Non-cancer C


title: XB0394 Non-cancer C


title: XB0402 Non-cancer C


title: XB0436 Non-cancer C


title: XB0380 Non-cancer C


title: XB0427 Non-cancer C


title: XB0398 Non-cancer C


title: XB0511 Non-cancer C


title: XB0391 Non-cancer C


title: XB0341 Non-cancer C


title: XB0369 Non-cancer C


title: XB0490 Non-cancer C


title: XB0477 Non-cancer C


title: XB0332 Non-cancer C


title: XB0321 Non-cancer C


title: XB0281 Non-cancer C


title: XB0283 Non-cancer C


title: XB0318 Non-cancer C


title: XB0274 Non-cancer C


title: XB0260 Non-cancer C


title: XB0287 Non-cancer C


title: XB0258 Non-cancer C


title: XB0344 Non-cancer C


title: XB0252 Non-cancer C


title: XB0250 Non-cancer C


title: XB0203 Non-cancer C


title: XB0334 Non-cancer C


title: XB0190 Non-cancer C


title: XB0206 Non-cancer C


title: XB0197 Non-cancer C


title: XB0198 Non-cancer C


title: XB0194 Non-cancer C


title: XB0195 Non-cancer C


title: XB0191 Non-cancer C


title: XB0189 Non-cancer C


title: XB0219 Non-cancer C


title: XB0232 Non-cancer C


title: XB0196 Non-cancer C


title: XB0187 Non-cancer C


title: XB0182 Non-cancer C


title: XB0183 Non-cancer C


title: XB0186 Non-cancer C


title: XB0184 Non-cancer C


title: XB0173 Non-cancer C


title: XB0178 Non-cancer C


title: XB0180 Non-cancer C


title: XB0181 Non-cancer C


title: XB0185 Non-cancer C


title: XB0174 Non-cancer C


title: XB0176 Non-cancer C


title: XB0188 Non-cancer C


title: XB0172 Non-cancer C


title: XB0171 Non-cancer C


title: XB0170 Non-cancer C


title: XB0158 Non-cancer C


title: XB0163 Non-cancer C


title: XB0160 Non-cancer C


title: XB0165 Non-cancer C


title: XB0166 Non-cancer C


title: XB0156 Non-cancer C


title: XB0154 Non-cancer C


title: XB0161 Non-cancer C


title: XB0159 Non-cancer C


title: XB0155 Non-cancer C


title: XB0153 Non-cancer C


title: XB0145 Non-cancer C


title: XB0143 Non-cancer C


title: XB0151 Non-cancer C


title: XB0142 Non-cancer C


title: XB0147 Non-cancer C


title: XB0149 Non-cancer C


title: XB0138 Non-cancer C


title: XB0137 Non-cancer C


title: XB0141 Non-cancer C


title: XB0135 Non-cancer C


title: XB0136 Non-cancer C


title: XB0134 Non-cancer C


title: XB0169 Non-cancer C


title: XB0162 Non-cancer C


title: XB0130 Non-cancer C


title: XB0126 Non-cancer C


title: XB0125 Non-cancer C


title: XB0129 Non-cancer C


title: XB0148 Non-cancer C


title: XB0119 Non-cancer C


title: XB0121 Non-cancer C


title: XB0120 Non-cancer C


title: XB0123 Non-cancer C


title: XB0124 Non-cancer C


title: XB0115 Non-cancer C


title: XB0117 Non-cancer C


title: XB0107 Non-cancer C


title: XB0118 Non-cancer C


title: XB0106 Non-cancer C


title: XB0105 Non-cancer C


title: XB0099 Non-cancer C


title: XB0102 Non-cancer C


title: XB0098 Non-cancer C


title: XB0097 Non-cancer C


title: XB0100 Non-cancer C


title: XB0096 Non-cancer C


title: XB0090 Non-cancer C


title: XB0094 Non-cancer C


title: XB0083 Non-cancer C


title: XB0087 Non-cancer C


title: XB0081 Non-cancer C


title: XB0080 Non-cancer C


title: XB0082 Non-cancer C


title: XB0088 Non-cancer C


title: XB0103 Non-cancer C


title: XB0079 Non-cancer C


title: XB0101 Non-cancer C


title: XB0078 Non-cancer C


title: XB0075 Non-cancer C


title: XB0073 Non-cancer C


title: XB0072 Non-cancer C


title: XB0068 Non-cancer C


title: XB0069 Non-cancer C


title: XB0070 Non-cancer C


title: XB0064 Non-cancer C


title: XB0063 Non-cancer C


title: XB0056 Non-cancer C


title: XB0052 Non-cancer C


title: XB0045 Non-cancer C


title: XB0051 Non-cancer C


title: XB0047 Non-cancer C


title: XB0071 Non-cancer C


title: XB0035 Non-cancer C


title: XB0039 Non-cancer C


title: XB0037 Non-cancer C


title: XB0038 Non-cancer C


title: XB0084 Non-cancer C


title: XB0034 Non-cancer C


title: XB0040 Non-cancer C


title: XB0043 Non-cancer C


title: XB0036 Non-cancer C


title: XB0028 Non-cancer C


title: XB0029 Non-cancer C


title: XB0021 Non-cancer C


title: XB0020 Non-cancer C


title: XB0030 Non-cancer C


title: XB0031 Non-cancer C


title: XB0017 Non-cancer C


title: XB0023 Non-cancer C


title: XB0024 Non-cancer C


title: XB0016 Non-cancer C


title: XB0054 Non-cancer C


title: XB0013 Non-cancer C


title: XB0014 Non-cancer C


title: XB0032 Non-cancer C


title: XB0022 Non-cancer C


title: XB0010 Non-cancer C


title: XB0008 Non-cancer C


title: XB0007 Non-cancer C


title: XB0003 Non-cancer C


title: XA0996 Non-cancer C


title: XB0012 Non-cancer C


title: XA0998 Non-cancer C


title: XA0992 Non-cancer C


title: XA0995 Non-cancer C


title: XA0994 Non-cancer C


title: XA0993 Non-cancer C


title: XA0991 Non-cancer C


title: XA0990 Non-cancer C


title: XA0980 Non-cancer C


title: XA0977 Non-cancer C


title: XA0978 Non-cancer C


title: XA0981 Non-cancer C


title: XA0987 Non-cancer C


title: XA0979 Non-cancer C


title: XA0983 Non-cancer C


title: XA0985 Non-cancer C


title: XA0976 Non-cancer C


title: XA0973 Non-cancer C


title: XA0972 Non-cancer C


title: XA0964 Non-cancer C


title: XA0971 Non-cancer C


title: XA0989 Non-cancer C


title: XB0018 Non-cancer C


title: XA0970 Non-cancer C


title: XA0963 Non-cancer C


title: XA0967 Non-cancer C


title: XA0959 Non-cancer C


title: XA0988 Non-cancer C


title: XA0961 Non-cancer C


title: XA0962 Non-cancer C


title: XA0975 Non-cancer C


title: XA0957 Non-cancer C


title: XA0968 Non-cancer C


title: XA0951 Non-cancer C


title: XA0948 Non-cancer C


title: XA0949 Non-cancer C


title: XA0955 Non-cancer C


title: XA0956 Non-cancer C


title: XA0940 Non-cancer C


title: XA0935 Non-cancer C


title: XA0929 Non-cancer C


title: XA0933 Non-cancer C


title: XA0927 Non-cancer C


title: XA0932 Non-cancer C


title: XA0934 Non-cancer C


title: XA0923 Non-cancer C


title: XA0921 Non-cancer C


title: XA0958 Non-cancer C


title: XA0920 Non-cancer C


title: XA0917 Non-cancer C


title: XA0916 Non-cancer C


title: XA0953 Non-cancer C


title: XA0931 Non-cancer C


title: XA0915 Non-cancer C


title: XA0943 Non-cancer C


title: XA0908 Non-cancer C


title: XA0907 Non-cancer C


title: XA0913 Non-cancer C


title: XA0909 Non-cancer C


title: XA0900 Non-cancer C


title: XA0898 Non-cancer C


title: XA0901 Non-cancer C


title: XA0899 Non-cancer C


title: XA0897 Non-cancer C


title: XA0942 Non-cancer C


title: XA0878 Non-cancer C


title: XA0873 Non-cancer C


title: XA0881 Non-cancer C


title: XA0875 Non-cancer C


title: XA0879 Non-cancer C


title: XA0911 Non-cancer C


title: XA0919 Non-cancer C


title: XA0880 Non-cancer C


title: XA0905 Non-cancer C


title: XA0871 Non-cancer C


title: XA0863 Non-cancer C


title: XA0865 Non-cancer C


title: XA0861 Non-cancer C


title: XA0862 Non-cancer C


title: XA0860 Non-cancer C


title: XA0857 Non-cancer C


title: XA0904 Non-cancer C


title: XA0891 Non-cancer C


title: XA0895 Non-cancer C


title: XA0856 Non-cancer C


title: XA0848 Non-cancer C


title: XA0836 Non-cancer C


title: XA0869 Non-cancer C


title: XA0852 Non-cancer C


title: XA0839 Non-cancer C


title: XA0817 Non-cancer C


title: XA0821 Non-cancer C


title: XA0797 Non-cancer C


title: XA0809 Non-cancer C


title: XA0888 Non-cancer C


title: XA0829 Non-cancer C


title: XA0832 Non-cancer C


title: XA0831 Non-cancer C


title: XA0826 Non-cancer C


title: XA0824 Non-cancer C


title: XA0804 Non-cancer C


title: XA0827 Non-cancer C


title: XA0803 Non-cancer C


title: XA0793 Non-cancer C


title: XA0800 Non-cancer C


title: XA0845 Non-cancer C


title: XA0851 Non-cancer C


title: XA0787 Non-cancer C


title: XA0795 Non-cancer C


title: XA0769 Non-cancer C


title: XA0749 Non-cancer C


title: XA0761 Non-cancer C


title: XA0744 Non-cancer C


title: XA0742 Non-cancer C


title: XA0813 Non-cancer C


title: XA0822 Non-cancer C


title: XA0730 Non-cancer C


title: XA0717 Non-cancer C


title: XA0708 Non-cancer C


title: XA0724 Non-cancer C


title: XA0706 Non-cancer C


title: XA0612 Non-cancer C


title: XA0694 Non-cancer C


title: XA0670 Non-cancer C


title: XA0564 Non-cancer C


title: XA0606 Non-cancer C


title: XA0681 Non-cancer C


title: XA0583 Non-cancer C


title: XA0559 Non-cancer C


title: XA0669 Non-cancer C


title: XA0659 Non-cancer C


title: XA0621 Non-cancer C


title: XA0622 Non-cancer C


title: XA0628 Non-cancer C


title: XA0644 Non-cancer C


title: XA0555 Non-cancer C


title: XA0562 Non-cancer C


title: XA0540 Non-cancer C


title: XA0543 Non-cancer C


title: XA0534 Non-cancer C


title: XA0548 Non-cancer C


title: XA0635 Non-cancer C


title: XA0512 Non-cancer C


title: XA0508 Non-cancer C


title: XA0651 Non-cancer C


title: XA0489 Non-cancer C


title: XA0483 Non-cancer C


title: XA0506 Non-cancer C


title: XA0502 Non-cancer C


title: XA0507 Non-cancer C


title: XA0464 Non-cancer C


title: XA0458 Non-cancer C


title: XA0436 Non-cancer C


title: XA0457 Non-cancer C


title: XA0451 Non-cancer C


title: XA0313 Non-cancer C


title: XA0297 Non-cancer C


title: XA0299 Non-cancer C


title: XA0377 Non-cancer C


title: XA0366 Non-cancer C


title: XA0296 Non-cancer C


title: XA0232 Non-cancer C


title: XA0264 Non-cancer C


title: XA0267 Non-cancer C


title: XA0384 Non-cancer C


title: XA0113 Non-cancer C


title: XA0196 Non-cancer C


title: XA0182 Non-cancer C


title: XA0115 Non-cancer C


title: XA0295 Non-cancer C


title: XA0468 Non-cancer C


title: XA0275 Non-cancer C


title: XA0417 Non-cancer C


title: XA0391 Non-cancer C


title: XA0030 Non-cancer C


title: GL0254 Non-cancer A

value: Non-cancer A


title: GL0242 Non-cancer A


title: XA0088 Non-cancer C


title: GL0241 Non-cancer A


title: GL0211 Non-cancer A


title: GL0214 Non-cancer A


title: GL0216 Non-cancer A


title: GL0209 Non-cancer A


title: GL0206 Non-cancer A


title: GL0297 Non-cancer A


title: GL0207 Non-cancer A


title: GL0212 Non-cancer A


title: GL0204 Non-cancer A


title: GL0203 Non-cancer A


title: BC1347 Non-cancer A


title: XA0140 Non-cancer C


title: SA0972 Non-cancer A


title: SA0962 Non-cancer A


title: SA0989 Non-cancer A


title: BC0921 Non-cancer A


title: SA0980 Non-cancer A


title: BC1269 Non-cancer A


title: SA0952 Non-cancer A


title: SA0941 Non-cancer A


title: SA0932 Non-cancer A


title: SA0927 Non-cancer A


title: SA0925 Non-cancer A


title: SA0913 Non-cancer A


title: SA0916 Non-cancer A


title: SA0899 Non-cancer A


title: SA0914 Non-cancer A


title: SA0905 Non-cancer A


title: SA0860 Non-cancer A


title: SA0895 Non-cancer A


title: SA0911 Non-cancer A


title: SA0909 Non-cancer A


title: SA0854 Non-cancer A


title: SA0842 Non-cancer A


title: SA0840 Non-cancer A


title: SA0823 Non-cancer A


title: SA0827 Non-cancer A


title: SA0858 Non-cancer A


title: SA0837 Non-cancer A


title: SA0841 Non-cancer A


title: SA0821 Non-cancer A


title: SA0818 Non-cancer A


title: SA0817 Non-cancer A


title: SA0822 Non-cancer A


title: SA0836 Non-cancer A


title: SA0833 Non-cancer A


title: SA0812 Non-cancer A


title: SA0807 Non-cancer A


title: SA0803 Non-cancer A


title: SA0808 Non-cancer A


title: SA0810 Non-cancer A


title: SA0798 Non-cancer A


title: SA0792 Non-cancer A


title: SA0788 Non-cancer A


title: SA0784 Non-cancer A


title: SA0786 Non-cancer A


title: SA0785 Non-cancer A


title: SA0797 Non-cancer A


title: SA0814 Non-cancer A


title: SA0790 Non-cancer A


title: SA0795 Non-cancer A


title: SA0796 Non-cancer A


title: SA0780 Non-cancer A


title: SA0760 Non-cancer A


title: SA0775 Non-cancer A


title: SA0783 Non-cancer A


title: SA0769 Non-cancer A


title: SA0773 Non-cancer A


title: SA0767 Non-cancer A


title: SA0830 Non-cancer A


title: SA0778 Non-cancer A


title: SA0759 Non-cancer A


title: SA0755 Non-cancer A


title: SA0758 Non-cancer A


title: SA0794 Non-cancer A


title: SA0745 Non-cancer A


title: SA0740 Non-cancer A


title: SA0756 Non-cancer A


title: SA0742 Non-cancer A


title: SA0726 Non-cancer A


title: SA0752 Non-cancer A


title: SA0743 Non-cancer A


title: SA0753 Non-cancer A


title: SA0732 Non-cancer A


title: SA0750 Non-cancer A


title: SA0715 Non-cancer A


title: SA0736 Non-cancer A


title: SA0747 Non-cancer A


title: SA0727 Non-cancer A


title: SA0723 Non-cancer A


title: SA0703 Non-cancer A


title: SA0725 Non-cancer A


title: SA0722 Non-cancer A


title: SA0700 Non-cancer A


title: SA0721 Non-cancer A


title: SA0717 Non-cancer A


title: SA0689 Non-cancer A


title: SA0693 Non-cancer A


title: SA0707 Non-cancer A


title: SA0714 Non-cancer A


title: SA0711 Non-cancer A


title: SA0713 Non-cancer A


title: SA0710 Non-cancer A


title: SA0699 Non-cancer A


title: SA0705 Non-cancer A


title: SA0704 Non-cancer A


title: SA0679 Non-cancer A


title: SA0673 Non-cancer A


title: SA0670 Non-cancer A


title: SA0674 Non-cancer A


title: SA0667 Non-cancer A


title: SA0678 Non-cancer A


title: SA0684 Non-cancer A


title: SA0663 Non-cancer A


title: SA0671 Non-cancer A


title: SA0676 Non-cancer A


title: SA0665 Non-cancer A


title: SA0664 Non-cancer A


title: SA0688 Non-cancer A


title: SA0654 Non-cancer A


title: SA0656 Non-cancer A


title: SA0661 Non-cancer A


title: SA0658 Non-cancer A


title: SA0655 Non-cancer A


title: SA0685 Non-cancer A


title: SA0660 Non-cancer A


title: SA0651 Non-cancer A


title: SA0649 Non-cancer A


title: SA0677 Non-cancer A


title: SA0644 Non-cancer A


title: SA0635 Non-cancer A


title: SA0643 Non-cancer A


title: SA0647 Non-cancer A


title: SA0648 Non-cancer A


title: SA0619 Non-cancer A


title: SA0624 Non-cancer A


title: SA0639 Non-cancer A


title: SA0638 Non-cancer A


title: SA0617 Non-cancer A


title: SA0642 Non-cancer A


title: SA0641 Non-cancer A


title: SA0621 Non-cancer A


title: SA0640 Non-cancer A


title: SA0615 Non-cancer A


title: SA0613 Non-cancer A


title: SA0610 Non-cancer A


title: SA0611 Non-cancer A


title: SA0633 Non-cancer A


title: SA0630 Non-cancer A


title: SA0629 Non-cancer A


title: SA0612 Non-cancer A


title: SA0608 Non-cancer A


title: SA0607 Non-cancer A


title: SA0636 Non-cancer A


title: SA0605 Non-cancer A


title: SA0604 Non-cancer A


title: SA0627 Non-cancer A


title: SA0599 Non-cancer A


title: SA0600 Non-cancer A


title: SA0595 Non-cancer A


title: SA0588 Non-cancer A


title: SA0573 Non-cancer A


title: SA0582 Non-cancer A


title: SA0587 Non-cancer A


title: SA0583 Non-cancer A


title: SA0571 Non-cancer A


title: SA0574 Non-cancer A


title: SA0576 Non-cancer A


title: SA0590 Non-cancer A


title: SA0593 Non-cancer A


title: SA0592 Non-cancer A


title: SA0569 Non-cancer A


title: SA0570 Non-cancer A


title: SA0598 Non-cancer A


title: SA0568 Non-cancer A


title: SA0591 Non-cancer A


title: SA0594 Non-cancer A


title: SA0554 Non-cancer A


title: SA0566 Non-cancer A


title: SA0549 Non-cancer A


title: SA0560 Non-cancer A


title: SA0548 Non-cancer A


title: SA0578 Non-cancer A


title: SA0559 Non-cancer A


title: SA0544 Non-cancer A


title: SA0556 Non-cancer A


title: SA0562 Non-cancer A


title: SA0539 Non-cancer A


title: SA0545 Non-cancer A


title: SA0532 Non-cancer A


title: SA0537 Non-cancer A


title: SA0533 Non-cancer A


title: SA0565 Non-cancer A


title: SA0531 Non-cancer A


title: SA0524 Non-cancer A


title: SA0530 Non-cancer A


title: SA0521 Non-cancer A


title: SA0522 Non-cancer A


title: SA0526 Non-cancer A


title: SA0520 Non-cancer A


title: SA0514 Non-cancer A


title: SA0515 Non-cancer A


title: SA0516 Non-cancer A


title: SA0517 Non-cancer A


title: SA0511 Non-cancer A


title: SA0512 Non-cancer A


title: SA0563 Non-cancer A


title: SA0503 Non-cancer A


title: SA0491 Non-cancer A


title: SA0494 Non-cancer A


title: SA0507 Non-cancer A


title: SA0499 Non-cancer A


title: SA0496 Non-cancer A


title: SA0500 Non-cancer A


title: SA0490 Non-cancer A


title: SA0523 Non-cancer A


title: SA0509 Non-cancer A


title: SA0485 Non-cancer A


title: SA0486 Non-cancer A


title: SA0482 Non-cancer A


title: PR1285 Non-cancer A


title: PR1283 Non-cancer A


title: PR1284 Non-cancer A


title: SA0475 Non-cancer A


title: SA0488 Non-cancer A


title: PR1276 Non-cancer A


title: PR1280 Non-cancer A


title: PR1281 Non-cancer A


title: PR1278 Non-cancer A


title: SA0483 Non-cancer A


title: PR1275 Non-cancer A


title: PR1270 Non-cancer A


title: PR1282 Non-cancer A


title: SA0495 Non-cancer A


title: PR1272 Non-cancer A


title: PR1268 Non-cancer A


title: PR1274 Non-cancer A


title: PR1273 Non-cancer A


title: PR1266 Non-cancer A


title: PR1279 Non-cancer A


title: PR1264 Non-cancer A


title: PR1271 Non-cancer A


title: PR1261 Non-cancer A


title: PR1259 Non-cancer A


title: PR1267 Non-cancer A


title: SA0477 Non-cancer A


title: SA0473 Non-cancer A


title: PR1265 Non-cancer A


title: PR1256 Non-cancer A


title: PR1262 Non-cancer A


title: PR1263 Non-cancer A


title: PR1252 Non-cancer A


title: SA0472 Non-cancer A


title: PR1250 Non-cancer A


title: PR1277 Non-cancer A


title: PR1260 Non-cancer A


title: PR1246 Non-cancer A


title: PR1241 Non-cancer A


title: PR1242 Non-cancer A


title: PR1269 Non-cancer A


title: PR1257 Non-cancer A


title: PR1238 Non-cancer A


title: PR1255 Non-cancer A


title: PR1248 Non-cancer A


title: PR1233 Non-cancer A


title: PR1231 Non-cancer A


title: PR1251 Non-cancer A


title: PR1229 Non-cancer A


title: PR1254 Non-cancer A


title: PR1249 Non-cancer A


title: PR1253 Non-cancer A


title: PR1244 Non-cancer A


title: PR1236 Non-cancer A


title: PR1243 Non-cancer A


title: PR1226 Non-cancer A


title: PR1227 Non-cancer A


title: PR1245 Non-cancer A


title: PR1240 Non-cancer A


title: PR1224 Non-cancer A


title: PR1237 Non-cancer A


title: PR1239 Non-cancer A


title: PR1223 Non-cancer A


title: PR1234 Non-cancer A


title: PR1232 Non-cancer A


title: PR1235 Non-cancer A


title: PR1230 Non-cancer A


title: PR1225 Non-cancer A


title: PR1228 Non-cancer A


title: PR1220 Non-cancer A


title: PR1216 Non-cancer A


title: PR1219 Non-cancer A


title: PR1210 Non-cancer A


title: PR1212 Non-cancer A


title: PR1206 Non-cancer A


title: PR1222 Non-cancer A


title: PR1218 Non-cancer A


title: PR1221 Non-cancer A


title: PR1215 Non-cancer A


title: PR1213 Non-cancer A


title: PR1214 Non-cancer A


title: PR1199 Non-cancer A


title: PR1217 Non-cancer A


title: PR1198 Non-cancer A


title: PR1195 Non-cancer A


title: PR1192 Non-cancer A


title: PR1204 Non-cancer A


title: PR1191 Non-cancer A


title: PR1207 Non-cancer A


title: PR1211 Non-cancer A


title: PR1208 Non-cancer A


title: PR1209 Non-cancer A


title: PR1203 Non-cancer A


title: PR1205 Non-cancer A


title: PR1184 Non-cancer A


title: PR1185 Non-cancer A


title: PR1187 Non-cancer A


title: PR1200 Non-cancer A


title: PR1181 Non-cancer A


title: PR1202 Non-cancer A


title: PR1179 Non-cancer A


title: PR1197 Non-cancer A


title: PR1201 Non-cancer A


title: PR1194 Non-cancer A


title: PR1193 Non-cancer A


title: PR1176 Non-cancer A


title: PR1190 Non-cancer A


title: PR1196 Non-cancer A


title: PR1189 Non-cancer A


title: PR1173 Non-cancer A


title: PR1168 Non-cancer A


title: PR1167 Non-cancer A


title: PR1170 Non-cancer A


title: PR1169 Non-cancer A


title: PR1183 Non-cancer A


title: PR1182 Non-cancer A


title: PR1165 Non-cancer A


title: PR1178 Non-cancer A


title: PR1163 Non-cancer A


title: PR1188 Non-cancer A


title: PR1186 Non-cancer A


title: PR1177 Non-cancer A


title: PR1180 Non-cancer A


title: PR1174 Non-cancer A


title: PR1157 Non-cancer A


title: PR1166 Non-cancer A


title: PR1164 Non-cancer A


title: PR1162 Non-cancer A


title: PR1158 Non-cancer A


title: PR1147 Non-cancer A


title: PR1159 Non-cancer A


title: PR1148 Non-cancer A


title: PR1161 Non-cancer A


title: PR1146 Non-cancer A


title: PR1160 Non-cancer A


title: PR1145 Non-cancer A


title: PR1141 Non-cancer A


title: PR1140 Non-cancer A


title: PR1144 Non-cancer A


title: PR1154 Non-cancer A


title: PR1153 Non-cancer A


title: PR1150 Non-cancer A


title: PR1151 Non-cancer A


title: PR1137 Non-cancer A


title: PR1143 Non-cancer A


title: PR1136 Non-cancer A


title: PR1135 Non-cancer A


title: PR1142 Non-cancer A


title: PR1139 Non-cancer A


title: PR1171 Non-cancer A


title: PR1156 Non-cancer A


title: PR1152 Non-cancer A


title: PR1133 Non-cancer A


title: PR1134 Non-cancer A


title: PR1138 Non-cancer A


title: PR1132 Non-cancer A


title: PR1131 Non-cancer A


title: PR1123 Non-cancer A


title: PR1129 Non-cancer A


title: PR1127 Non-cancer A


title: PR1122 Non-cancer A


title: PR1128 Non-cancer A


title: PR1121 Non-cancer A


title: PR1116 Non-cancer A


title: PR1130 Non-cancer A


title: PR1124 Non-cancer A


title: PR1119 Non-cancer A


title: PR1120 Non-cancer A


title: PR1114 Non-cancer A


title: PR1111 Non-cancer A


title: PR1112 Non-cancer A


title: PR1105 Non-cancer A


title: PR1113 Non-cancer A


title: PR1106 Non-cancer A


title: PR1109 Non-cancer A


title: PR1125 Non-cancer A


title: PR1126 Non-cancer A


title: PR1108 Non-cancer A


title: PR1107 Non-cancer A


title: PR1104 Non-cancer A


title: PR1110 Non-cancer A


title: PR1103 Non-cancer A


title: PR1102 Non-cancer A


title: PR1099 Non-cancer A


title: PR1098 Non-cancer A


title: PR1096 Non-cancer A


title: PR1094 Non-cancer A


title: PR1095 Non-cancer A


title: PR1100 Non-cancer A


title: PR1101 Non-cancer A


title: PR1093 Non-cancer A


title: PR1092 Non-cancer A


title: PR1088 Non-cancer A


title: PR1091 Non-cancer A


title: PR1089 Non-cancer A


title: PR1086 Non-cancer A


title: PR1079 Non-cancer A


title: PR1082 Non-cancer A


title: PR1077 Non-cancer A


title: PR1085 Non-cancer A


title: PR1083 Non-cancer A


title: PR1075 Non-cancer A


title: PR1073 Non-cancer A


title: PR1078 Non-cancer A


title: PR1080 Non-cancer A


title: PR1081 Non-cancer A


title: PR1074 Non-cancer A


title: PR1072 Non-cancer A


title: PR1076 Non-cancer A


title: PR1071 Non-cancer A


title: PR1069 Non-cancer A


title: PR1067 Non-cancer A


title: PR1068 Non-cancer A


title: PR1063 Non-cancer A


title: PR1064 Non-cancer A


title: PR1065 Non-cancer A


title: PR1118 Non-cancer A


title: PR1084 Non-cancer A


title: PR1057 Non-cancer A


title: PR1059 Non-cancer A


title: PR1061 Non-cancer A


title: PR1056 Non-cancer A


title: PR1053 Non-cancer A


title: PR1062 Non-cancer A


title: PR1055 Non-cancer A


title: PR1049 Non-cancer A


title: PR1050 Non-cancer A


title: PR1047 Non-cancer A


title: PR1052 Non-cancer A


title: PR1060 Non-cancer A


title: PR1058 Non-cancer A


title: PR1051 Non-cancer A


title: OV0421 Non-cancer A


title: OV0425 Non-cancer A


title: PR1054 Non-cancer A


title: PR1048 Non-cancer A


title: PR1046 Non-cancer A


title: PR1045 Non-cancer A


title: OV0437 Non-cancer A


title: OV0352 Non-cancer A


title: OV0426 Non-cancer A


title: OV0305 Non-cancer A


title: OV0356 Non-cancer A


title: OV0306 Non-cancer A


title: OV0341 Non-cancer A


title: OV0334 Non-cancer A


title: OV0358 Non-cancer A


title: OV0348 Non-cancer A


title: OV0428 Non-cancer A


title: OV0303 Non-cancer A


title: OV0328 Non-cancer A


title: OV0364 Non-cancer A


title: OV0276 Non-cancer A


title: OV0265 Non-cancer A


title: OV0270 Non-cancer A


title: OV0302 Non-cancer A


title: PR1115 Non-cancer A


title: OV0287 Non-cancer A


title: OV0286 Non-cancer A


title: OV0301 Non-cancer A


title: OV0289 Non-cancer A


title: OV0282 Non-cancer A


title: OV0267 Non-cancer A


title: OV0263 Non-cancer A


title: NB16020803 Non-cancer B

value: Non-cancer B


title: NB16021503 Non-cancer B


title: OV0268 Non-cancer A


title: NB16021904 Non-cancer B


title: NB16030301 Non-cancer B


title: NB16022906 Non-cancer B


title: NB16021607 Non-cancer B


title: NB16022605 Non-cancer B


title: NB16030202 Non-cancer B


title: NB16030102 Non-cancer B


title: NB16021505 Non-cancer B


title: NB16012205 Non-cancer B


title: NB16012203 Non-cancer B


title: NB16020902 Non-cancer B


title: NB16020402 Non-cancer B


title: NB16011907 Non-cancer B


title: NB16020805 Non-cancer B


title: NB16020401 Non-cancer B


title: NB16011503 Non-cancer B


title: NB16020103 Non-cancer B


title: NB15122103 Non-cancer B


title: NB15122201 Non-cancer B


title: NB16012609 Non-cancer B


title: NB16012207 Non-cancer B


title: NB15121601 Non-cancer B


title: NB16012204 Non-cancer B


title: NB16012503 Non-cancer B


title: NB16012607 Non-cancer B


title: NB16012103 Non-cancer B


title: NB16011505 Non-cancer B


title: NB15121108 Non-cancer B


title: NB15121103 Non-cancer B


title: NB16011401 Non-cancer B


title: NB15120406 Non-cancer B


title: NB15112403 Non-cancer B


title: PR1097 Non-cancer A


title: NB15120404 Non-cancer B


title: NB15121109 Non-cancer B


title: NB15122204 Non-cancer B


title: NB15121504 Non-cancer B


title: NB15121107 Non-cancer B


title: NB15121001 Non-cancer B


title: NB15121102 Non-cancer B


title: NB15111802 Non-cancer B


title: NB15120805 Non-cancer B


title: NB15111901 Non-cancer B


title: NB15112701 Non-cancer B


title: NB15082701 Non-cancer B


title: NB15102303 Non-cancer B


title: NB15102703 Non-cancer B


title: NB15112008 Non-cancer B


title: NB15090903 Non-cancer B


title: NB15111602 Non-cancer B


title: NB15111305 Non-cancer B


title: NB15110905 Non-cancer B


title: NB15111201 Non-cancer B


title: NB15110608 Non-cancer B


title: NB15091401 Non-cancer B


title: NB15112001 Non-cancer B


title: NB15090707 Non-cancer B


title: NB15101906 Non-cancer B


title: NB15070802 Non-cancer B


title: NB15070604 Non-cancer B


title: NB15063002 Non-cancer B


title: NB15073101 Non-cancer B


title: NB15062202 Non-cancer B


title: NB15081302 Non-cancer B


title: NB15081202 Non-cancer B


title: NB15081405 Non-cancer B


title: NB15041402 Non-cancer B


title: NB15032502 Non-cancer B


title: NB15032701 Non-cancer B


title: NB15032003 Non-cancer B


title: NB15041703 Non-cancer B


title: NB15073104 Non-cancer B


title: NB15042801 Non-cancer B


title: NB15031603 Non-cancer B


title: NB15040602 Non-cancer B


title: NB15012101 Non-cancer B


title: NB15022703 Non-cancer B


title: NB14102702 Non-cancer B


title: NB15020202 Non-cancer B


title: NB14093004 Non-cancer B


title: NB15033103 Non-cancer B


title: NB15031702 Non-cancer B


title: NB15020301 Non-cancer B


title: NB14090202 Non-cancer B


title: NB14102101 Non-cancer B


title: NB14100606 Non-cancer B


title: NB14051905 Non-cancer B


title: NB14092903 Non-cancer B


title: NB14100602 Non-cancer B


title: NB14050204 Non-cancer B


title: NB14050103 Non-cancer B


title: NB14051201 Non-cancer B


title: NB15030302 Non-cancer B


title: NB14072504 Non-cancer B


title: NB14072301 Non-cancer B


title: NB14041102 Non-cancer B


title: NB14040203 Non-cancer B


title: NB14071804 Non-cancer B


title: NB14040305 Non-cancer B


title: NB14071703 Non-cancer B


title: NB14031201 Non-cancer B


title: NB14071602 Non-cancer B


title: NB14051506 Non-cancer B


title: NB15011901 Non-cancer B


title: NB14050904 Non-cancer B


title: NB14041601 Non-cancer B


title: NB14041501 Non-cancer B


title: NB14040901 Non-cancer B


title: NB14040703 Non-cancer B


title: NB14030305 Non-cancer B


title: NB14012203 Non-cancer B


title: NB14012205 Non-cancer B


title: NB14012002 Non-cancer B


title: NB14011602 Non-cancer B


title: NB14020505 Non-cancer B


title: NB14042204 Non-cancer B


title: NB14012301 Non-cancer B


title: NB14012702 Non-cancer B


title: NB14012201 Non-cancer B


title: NB14012304 Non-cancer B


title: NB14011002 Non-cancer B


title: NB14011501 Non-cancer B


title: NB14011601 Non-cancer B


title: NB13120904 Non-cancer B


title: NB14022701 Non-cancer B


title: NB13122501 Non-cancer B


title: NB13120903 Non-cancer B


title: NB13121102 Non-cancer B


title: NB13120601 Non-cancer B


title: NB13121801 Non-cancer B


title: NB13121701 Non-cancer B


title: NB14010902 Non-cancer B


title: NB13121103 Non-cancer B


title: NB14010701 Non-cancer B


title: NB13120901 Non-cancer B


title: NB13112603 Non-cancer B


title: NB13120208 Non-cancer B


title: NB13111305 Non-cancer B


title: NB13121901 Non-cancer B


title: NB14010901 Non-cancer B


title: NB13112602 Non-cancer B


title: NB13111202 Non-cancer B


title: NB13120501 Non-cancer B


title: NB13112801 Non-cancer B


title: NB13102103 Non-cancer B


title: NB13102302 Non-cancer B


title: NB13112203 Non-cancer B


title: NB13101501 Non-cancer B


title: NB13090601 Non-cancer B


title: NB13111201 Non-cancer B


title: NB13102106 Non-cancer B


title: NB13110102 Non-cancer B


title: NB13111402 Non-cancer B


title: NB13101101 Non-cancer B


title: NB13112202 Non-cancer B


title: NB13090204 Non-cancer B


title: NB13090301 Non-cancer B


title: NB13091004 Non-cancer B


title: NB13090201 Non-cancer B


title: NB13081201 Non-cancer B